WO2016008440A1 - 含有13种甘油酯的薏苡仁油、制剂及其应用 - Google Patents

含有13种甘油酯的薏苡仁油、制剂及其应用 Download PDF

Info

Publication number
WO2016008440A1
WO2016008440A1 PCT/CN2015/084294 CN2015084294W WO2016008440A1 WO 2016008440 A1 WO2016008440 A1 WO 2016008440A1 CN 2015084294 W CN2015084294 W CN 2015084294W WO 2016008440 A1 WO2016008440 A1 WO 2016008440A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
coix seed
seed oil
injection
oil
Prior art date
Application number
PCT/CN2015/084294
Other languages
English (en)
French (fr)
Inventor
李大鹏
Original Assignee
浙江康莱特集团有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410342342.1A external-priority patent/CN105267776B/zh
Priority to AP2017009705A priority Critical patent/AP2017009705A0/en
Priority to CA2954688A priority patent/CA2954688C/en
Priority to NZ726577A priority patent/NZ726577A/en
Priority to KR1020177001301A priority patent/KR101893812B1/ko
Priority to EA201790116A priority patent/EA033751B1/ru
Application filed by 浙江康莱特集团有限公司 filed Critical 浙江康莱特集团有限公司
Priority to SG11201700120XA priority patent/SG11201700120XA/en
Priority to JP2017503165A priority patent/JP6473802B2/ja
Priority to PL15822401T priority patent/PL3153164T3/pl
Priority to AU2015291529A priority patent/AU2015291529B2/en
Priority to DK15822401.4T priority patent/DK3153164T3/da
Priority to EP15822401.4A priority patent/EP3153164B1/en
Publication of WO2016008440A1 publication Critical patent/WO2016008440A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Definitions

  • the invention relates to the field of pharmacy, in particular to a coix seed oil, a preparation, a preparation method thereof and application thereof in preparing an antitumor drug.
  • Coix seed is a mature dry seed of Coix lacryma-jobi L.var ma-yuen (Roman.) Stapf. It is a diuretic drug for a long time. Modern research has found that Coix seed has pharmacological effects such as analgesic, anti-inflammatory, immune regulation, anti-ulcer, hypolipidemic and weight loss. In recent years, domestic and foreign scholars have studied the chemical constituents of Coix seed by TLC, HPLC-MS, GC and other methods, and found that it contains a variety of active ingredients, including coix seed esters, triglycerides, fatty acids, lactams. Compounds such as terpenoids, saccharides, sterols, and triterpenoids.
  • esters are the first to be found to have anti-tumor activity, and are also the most reported chemical components.
  • Kanglaite injection which is currently used as an active ingredient in Chinese herbal medicine, has been widely used, its use of coix seed oil is complicated, and contains triglyceride and diglyceride in addition to triglyceride. And fatty acid esters, etc., which will inevitably pose great challenges to quality control and clinical drug safety in the actual production process.
  • the invention uses the hazelnut powder as a raw material, adopts the steps of supercritical carbon dioxide extraction, alkalization, neutral alumina and kaolin purification to obtain an effective part of coix seed oil; by separating and identifying the active components thereof, it is determined.
  • the composition is mainly composed of eight triglyceride components and five diglyceride components; and further physical and chemical constants are determined, and the optimal acid value, iodine value, saponification value, refractive index and relative density are determined.
  • the use of the coix seed oil of the invention is determined by the composition and composition, and the quality stability between batches in industrial production is ensured.
  • the object of the present invention is to provide a coix seed oil extracted from coix seed, which is characterized in that the coix seed oil contains five kinds of diglyceride components and eight triglyceride components in the following mass percentages: 1,3-dioleic acid diglyceride 0.40-0.58%, 1-linoleic acid-3-oleic acid diglyceride 0.91 ⁇ 1.31%, 1,2-dioleic acid diglyceride 0.24 ⁇ 0.35%, 1- Oleic acid-2-linoleic acid diglyceride 0.66-0.95%, 1,2-dilinoleic acid glyceride 0.33-0.47%, trilinoleic acid glyceride 4.87-6.99%, 1-oleic acid-2,3- Dilinoleic acid glyceride 13.00 ⁇ 18.69%, 1-palmitic acid-2,3-dilinoleic acid glyceride 5.25 ⁇ 7.54%, 1,3-dioleic acid-2-linoleic acid gly
  • the mass percentage of the above five diglyceride components and eight triglyceride components is: 1,3-dioleic acid diglyceride 0.45-0.55%, 1-linoleic acid-3-oleic acid glycerol Diester 1.03 to 1.25%, 1,2-dioleic acid diglyceride 0.27 to 0.33%, 1-oleic acid-2-linoleic acid diglyceride 0.75 to 0.91%, 1,2-dilinoleic acid glyceride 0.37-0.45%, linoleic acid glyceride 5.47-6.69%, 1-oleic acid-2,3-dilinoleic acid glyceride 14.63 ⁇ 17.88%, 1-palmitic acid-2,3-dilinoleic acid glyceride 5.9 to 7.21%, 1,3-dioleic acid-2-linoleic acid glyceride 14.88 to 18.19%, 1-palmitic acid-2-linoleic acid-3-
  • the mass percentage of the above five diglyceride components and eight triglyceride components is: 1,3-dioleic acid diglyceride 0.49 to 0.51%, 1-linoleic acid-3-oleic acid Diglyceride 1.12 ⁇ 1.16%, 1,2-dioleic acid diglyceride 0.29 ⁇ 0.31%, 1-oleic acid-2-linoleic acid diglyceride 0.81 ⁇ 0.85%, 1,2-dilinoleic acid glycerin Ester 0.40 ⁇ 0.42%, trilinoleic acid glyceride 5.96 ⁇ 6.20%, 1-oleic acid-2,3-dilinoleic acid glyceride 15.93 ⁇ 16.58%, 1-palmitic acid-2,3-dilinoleic acid glycerin Ester 6.43 ⁇ 6.69%, 1,3-dioleic acid-2-linoleic acid glyceride 16.20 ⁇ 16.87%, 1-palmitic acid-2-linoleic acid-3-ole
  • the above content refers to the mass percentage of the diglyceride or triglyceride compound in the coix seed oil, according to the present invention.
  • the coix seed oil prepared by the method is used as a raw material, and five diglyceride monomer compounds and eight triglyceride monomer compounds are obtained by preparative chromatography, and weighed and calculated. It can also be derived according to conventional analytical methods in the art.
  • the physicochemical constant of the eucalyptus oil is as follows: a relative density of 0.916 to 0.920 at 20 ° C, a refractive index of 1.471 to 1.474 at 20 ° C, an acid value of ⁇ 0.2, an iodine value of 100 to 106, and a saponification value of 186 to 195;
  • the coix seed oil of the present invention is obtained by the following method:
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 10 mesh to 80 mesh, and extracted by a 600 L ⁇ 2 supercritical CO 2 extractor.
  • the coix seed powder is charged into the extraction kettle, and the CO 2 preheater is heated by a jacketed circulating hot water.
  • the extraction kettle and the separation column are such that the extraction temperature and the separation temperature are respectively 33 to 45 ° C and 30 to 45 ° C, and the outlet temperatures of the first stage analytical reactor and the secondary analytical reactor are maintained at 20 to 50 ° C and 15 to 35 ° C, respectively;
  • the CO 2 fluid enters the separation column, and the pressure of the separation column is controlled to be 7-10 Mpa, and the coix seed oil is separated.
  • the CO 2 gas from the separation column enters the primary and secondary analytical reactors, respectively, and the pressure is maintained at 5-7 Mpa and 4-6 Mpa respectively. Discarding the impurities such as moisture obtained by analysis, the CO 2 gas is converted into liquid CO 2 through a condenser, recycled, and continuously extracted for 2 to 3 hours to obtain coix seed oil;
  • Refining Take the coix seed oil obtained by supercritical CO 2 extraction, add 60% of the oil weight of 60 ° C ⁇ 90 ° C petroleum ether, and then add the oil weight 36% ⁇ 56% of 2% NaOH solution according to the acid value, after stirring for 10 min After standing for 18 to 24 hours, the lower layer of soap is removed, and the upper layer is washed with purified water, and after standing for 18 to 24 hours, the lower layer of wastewater is removed; the upper layer is taken for the second water washing, and after standing for 40 to 50 hours, the lower layer of wastewater is removed.
  • the lower layer of wastewater is removed; the upper layer of oil is heated under reduced pressure and dried under reduced pressure, and then the activated neutral alumina is added with an oil weight of 8% to 12%, stirred, placed in a cold place, filtered, and filtered. Under nitrogen-filled conditions, it is concentrated under heating and reduced pressure, and then dried at 160-170 ° C under reduced pressure.
  • the bacteria are 1-2 hours, cooled and filtered through a 0.2 ⁇ m microporous membrane, and dispensed into a 500 ml glass infusion bottle, filled with nitrogen, sealed, and obtained;
  • the refining step is as follows:
  • the coix seed oil obtained by supercritical CO 2 extraction is added with 60% of oil weight 60 ° C ⁇ 90 ° C petroleum ether, and then according to the acid value, adding oil weight 36% ⁇ 56% 2% NaOH solution, stirring for 10 min, then static After 20h, the lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 22 hours, the lower layer of wastewater was removed. The upper layer was taken for the second water washing. After standing for 46 hours, the lower layer of wastewater was removed. The upper layer was refilled by 70%.
  • the coix seed oil of the invention is a pale yellow clear liquid with slight gas and mild taste; it is very soluble in petroleum ether or chloroform, soluble in acetone, slightly soluble in ethanol, and insoluble in water.
  • the coix seed oil prepared according to the method of the present invention is tested according to an appendix method of the Chinese Pharmacopoeia 2010 edition, and the physical and chemical constants thereof are: relative density of 0.916 to 0.920 at 20 ° C, and refractive index of 1.471 to 1.474 at 20 ° C, acid The value is ⁇ 0.2, the iodine value is 100 to 106, and the saponification value is 186 to 195.
  • the acid value in the pharmacopoeia refers to the weight (mg) of potassium hydroxide required to neutralize the free fatty acid contained in 1 gram of fat, fatty oil or the like. In the quality study of oil and fat products, the acid value is an important evaluation index.
  • the acid value is less than 0.2, that is, the purification process by supercritical extraction parameters and alkalization in the preparation process.
  • the prepared hazelnut oil has the following advantages: on the one hand, the free fatty acid content as an impurity is extremely low, and the finished product quality is good; on the other hand, a large amount of active components of diglyceride and triglyceride are enriched, and the purity is high. And wherein the diglyceride and triglyceride components are clear in type and stable in content.
  • the preparation method of the invention has high yield, low cost, stable product, is suitable for industrial production, and is safe and controllable.
  • the pharmaceutically acceptable carrier includes conventional diluents, excipients, fillers, emulsifiers, binders, lubricants, absorption enhancers, surfactants, disintegrants, lubricants or An antioxidant, if necessary, a flavoring agent, a sweetener, a preservative or a coloring agent.
  • the pharmaceutically acceptable carrier may be selected from the group consisting of: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, soybean phospholipid, vitamin C, vitamin E , EDTA disodium, EDTA calcium sodium, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, hydroxybenzene Ethyl ester solution, benzoic acid, potassium sorbate, chlorhexidine acetate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and Derivatives, alginate, gelatin, polyvin
  • the pharmaceutical preparation may be an oral solid preparation, an oral liquid preparation or an injection.
  • the oral solid preparation is selected from the group consisting of a capsule, a tablet, a dropping pill, a granule, and a concentrated pill;
  • the oral liquid preparation is selected from an aqueous or oily suspension, a solution, an emulsion, a syrup or an elixir, or It is a dry product which can be formulated with water or other suitable carrier before use;
  • the injection is selected from one of a nanosuspension, a liposome, an emulsion, a lyophilized powder injection and an aqueous injection.
  • the injection comprises the following components: 50-350 g of the coix seed oil of the invention, 10-40 g of soybean phospholipid for injection or soybean lecithin for injection, glycerol for injection or 15-50 g of glycerin for injection, and water for injection is added. 1000ml.
  • coix seed oil the oil ester and the water phase are separately heated to 60-70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 5 to 12 MPa
  • the high pressure is 25 to 50 MPa.
  • the recycling homogenization 3 to 6 times, to 2 ⁇ m or less particles should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 4.8 ⁇ 8.5, preferably 6.8 ⁇ 7.0, most preferably 6.8 with NaOH or HCl ;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter cartridge of 3 ⁇ m or less, sterilized by nitrogen filling, and cooled.
  • the capsule comprises the following components: 200 to 800 g of coix seed oil, 0.20 to 0.60 g of an antioxidant and/or an emulsifier, and 1000 capsules.
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and preservative according to the weight ratio of 1:0.6 ⁇ 1.2:0.3 ⁇ 0.8:0.0001 ⁇ 0.01; glycerin, purified water and preservative (selected from 10% hydroxybenzene) Ethyl ester solution, one of benzoic acid, potassium sorbate and chlorhexidine acetate) is added to a plastic can, heated to 70 ° C ⁇ 90 ° C, then add gelatin, stir constantly, vacuum until gelatin is completely dissolved, will Glue filtration, stored at 56 ⁇ 62 ° C, spare;
  • Preparation of liquid medicine Add the formula amount of coix seed oil, antioxidant and/or emulsifier (antioxidant is vitamin E, emulsifier is Tween 80) into the batching tank, and stir constantly until it is evenly mixed;
  • antioxidant is vitamin E
  • emulsifier is Tween 80
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, and enter at 15 ⁇ 30°C and relative humidity less than 35%. After the pressure pellets are shaped, the pellets are dried, the pellets are removed, and the pellets are washed with 95% medicinal ethanol, and then dried until the water content is less than 12%. The unqualified capsules are removed by visual inspection, printed, and packaged.
  • the invention shows through the pharmacodynamic experiment that the coix seed oil and its preparation have different degrees of inhibition effects on various human tumor cell lines, and can be used as a medicine for treating tumor diseases.
  • the object of the present invention is to provide a above-mentioned coix seed oil, a pharmaceutical preparation alone or in combination with platinum, an alkylating agent, a difluoronucleoside, an antibiotic, a cytotoxic or a hormonal chemical antitumor drug. Application in anti-tumor or inflammatory drugs.
  • the platinum is preferably cisplatin or carboplatin
  • the alkylating agent is preferably cyclophosphamide
  • the difluoronucleoside is preferably gemcitabine hydrochloride
  • the antibiotics are preferably mitoxantrone, mitomycin, cytotoxic
  • the class is docetaxel, paclitaxel
  • the hormone is preferably leuprolide acetate
  • the tumor refers to early, middle or advanced lung cancer, liver cancer, pancreatic cancer, prostate cancer, ovarian cancer, breast cancer, sarcomatoid carcinoma Or carcinosarcoma
  • the inflammation refers to benign prostatic hyperplasia.
  • compositions of the invention and their formulations in combating tumors or treating inflammation are illustrated below by experimental data.
  • Cell lines PANC-1 (human pancreatic cancer cells), SKOV3 (human ovarian cancer cells), MCF-7 (human breast cancer cells), Bcap-37 (human breast cancer cells), SMMC-7721 (human liver cancer) Cells), HepG-2 (human liver cancer cells), A549 (human lung cancer cells), H460 (human lung cancer cells), the above cell lines were preserved by the Shanghai Pharmaceutical Industry Research Pharmacological Evaluation Research Center and maintained.
  • DMEM complete medium 10% newborn calf serum (GIBCO BRL), double antibody was added.
  • Trypsin purchased from Invitrogen, stored at -20 °C.
  • PBS Phosphate buffer
  • MTT (AMRESCO) solution A solution of 5 mg/ml was prepared with PBS.
  • Dissolving solution 10 ml of SDS, 5 ml of isobutanol and 0.1 ml of concentrated hydrochloric acid per 100 ml of deionized double distilled water.
  • the inhibitory effect of the sample on the above cell line was measured by the MTT method.
  • Cell culture 1 The cells were taken out from liquid nitrogen, rapidly thawed in a 37 ° C water bath, and the cells were transferred to a 10 ml sterile centrifuge tube in a sterile table to add 6 ml of the cell culture medium, and centrifuged at 1000 rpm for 5 minutes. Discard the supernatant, add 5-6 ml of cell culture medium to the pellet, pipette it to suspend it, transfer it to the cell culture flask, and place it in a 37 °C cell culture incubator.
  • the cells are trypsinized and washed, suspended in a medium containing 10% calf serum, counted by the trypan blue staining method, and the cell suspension is adjusted.
  • the density is 2 x 10 5 cells/ml.
  • Human lung cancer A549 cell line frozen in liquid nitrogen was collected and cultured at 37 ° C and 5% CO 2 after resuscitation. After subculture, the cells in logarithmic growth phase were prepared into a cell suspension of (1 ⁇ 2) ⁇ 10 7 cell / ml concentration with physiological saline, and inoculated into BALB / C nude mice (SPF grade, 18 ⁇ 20g, 6 weeks old, male) right subcutaneous. Under sterile conditions, the tumor tissue of the second generation xenograft model of human lung cancer A549, which grew vigorously in vivo, was cut into uniform pieces of 1 to 2 mm 3 size, and a trocar was used to inoculate a piece of the right sac of each nude mouse. .
  • the applied feed, litter, cage and contact equipment should be used after autoclaving, and the nude mice should be placed in a laminar flow rack. And began to dynamically observe and test tumor size and animal weight. The animals in each group were sacrificed in about three weeks, and the tumors were weighed.
  • the tumor inhibition rate was calculated according to the following formula:
  • Tumor inhibition rate% [(control group average tumor weight-average tumor weight of administration group)/control group average tumor weight] ⁇ 100% effect of combined medication Q value was calculated according to the formula of Jin:
  • E a+b is the tumor inhibition rate of the combined drug
  • E a and E b are the tumor inhibition rates of drug A and drug B, respectively.
  • the Q value of 0.85-1.15 is additive (+), and greater than 1.15 is enhanced (++).
  • the dosage of the injection of the invention is 25ml/kg, 12.5ml/kg, 6.25ml/kg, and is administered according to the iv ⁇ 10qd regimen, and the growth of human lung cancer A549 transplanted into nude mice is significantly inhibited.
  • the anti-tumor effect of the injection of the invention combined with cisplatin on human lung cancer A549 transplanted into nude mice is obviously stronger than that of the injection of the invention and cisplatin alone, and has obvious additive effect.
  • the human tumor liver cancer QGY cell line frozen in liquid nitrogen was taken and cultured at 37 ° C and 5% CO 2 after resuscitation. Others are the same as "two, two.”
  • the dosage of the injection of the invention is 25ml/kg, 12.5ml/kg, 6.25ml/kg, and is administered according to the iv ⁇ 10qd regimen, and the growth of human liver cancer QGY transplanted into nude mice is obviously inhibited.
  • the anti-tumor effect of the injection of the present invention combined with doxorubicin on human liver cancer QGY transplanted into nude mice is significantly stronger than that of the injection of the present invention and doxorubicin alone.
  • the human tumor liver cancer LM-3 cell line frozen in liquid nitrogen was taken and cultured under the condition of 37 ° C and 5% CO 2 after resuscitation. Others are the same as "two, two.”
  • the dosage of the injection of the invention is 25ml/kg, 12.5ml/kg, 6.25ml/kg, and is administered according to the iv ⁇ 10qd regimen, and the growth of human liver cancer LM-3 transplanted into nude mice is obviously inhibited.
  • the anti-tumor effect of the injection of the invention combined with cyclophosphamide on human liver cancer LM-3 transplanted into nude mice is obviously stronger than that of the injection of the invention and cyclophosphamide alone, and has obvious additive effect.
  • the human tumor liver cancer SMMC-7721 cell line frozen in liquid nitrogen was taken and cultured at 37 ° C and 5% CO 2 after resuscitation. Others are the same as "two, two.”
  • the dosage of the injection of the invention is 25ml/kg, 12.5ml/kg, 6.25ml/kg, and is administered according to the iv ⁇ 10qd regimen.
  • the growth of human liver cancer SMMC-7721 in nude mice was significantly inhibited.
  • Injection of the invention (specification: 100ml: 10g), cyclophosphamide (CTX), imitoril (DHAD), mitomycin (MMC), physiological saline;
  • CX cyclophosphamide
  • DHAD imitoril
  • MMC mitomycin
  • the well-grown S180 ascites was prepared and diluted with physiological saline 1:4 to prepare a cell suspension of about (1-2) ⁇ 10 7 cells/ml.
  • Each mouse was inoculated with 0.2 ml subcutaneously and randomly grouped as shown in Table 7. The dose is administered from the next day. The animals were sacrificed by cervical dislocation 10 days after inoculation, and the tumor masses were dissected. The tumor weights of each dose group were compared and the inhibition rate was calculated.
  • W256 carcinosarcoma inoculated in Wistar rats, 50-60g, female;
  • the vigorously-grown rat W256 ascites was prepared and diluted with physiological saline to prepare a cell suspension of about (1-2) ⁇ 10 7 cells/ml, which was inoculated subcutaneously into the right ankle of the rat, 0.2 ml/mouse, after inoculation.
  • the rats were randomly divided into groups and started to be administered. Two weeks later, the animals were dissected, and the tumors were weighed. The difference between the experimental group and the control group was compared, and the tumor weight inhibition rate was calculated.
  • the anti-tumor effect of the injection of the invention combined with CTX is obviously stronger than that of the injection of the invention and chemotherapy alone, and has obvious additive effect.
  • PENC-1 human pancreatic cancer cells inoculated in BALB/C nude mice, 16-18 g, female;
  • the well-grown PENC-1 human pancreatic cancer tumors were harvested and subcutaneously inoculated into 4 weeks old female BALB/C nude mice.
  • the mice were randomly divided into groups and started to be administered.
  • the mice were sacrificed 1 week after the administration was stopped, and the tumors were weighed.
  • the tumor weight inhibition rate was calculated by the difference from the control group.
  • the anti-tumor effect of the injection of the invention combined with gemcitabine hydrochloride is obviously stronger than that of the injection of the invention and chemotherapy alone, and has obvious additive effect.
  • FC-3M human prostate cancer inoculated in BALB/C nude mice, 17-21 g, male;
  • FC-3M tumors were prepared and homogenized with 1:4 saline. Each mouse was inoculated with 0.2 ml subcutaneously, randomly divided into groups and administered on the next day. The mice were sacrificed 21 days after inoculation. Weighing, comparing the difference between the experimental group and the control group, calculating the tumor weight inhibition rate.
  • the anti-tumor effect of the injection of the invention combined with Lupron is obviously stronger than that of the injection of the invention and chemotherapy alone, and has obvious additive effect.
  • Injection of the invention (specification: 100ml: 10g), docetaxel injection (Taxotere, specification: 20mg/bottle), physiological saline
  • Human breast cancer Bcap-37 inoculated in BALB/C nude mice (SPF grade), 18-20 g, female;
  • a well-grown Bcap-37 tumor mass was prepared and homogenized with physiological saline to prepare a cell suspension of (1-2) ⁇ 10 7 cell/ml concentration.
  • Each mouse was inoculated with 0.2 ml of the right iliac crest, randomly divided into groups and inoculated. After the 7th day of administration, the mice were sacrificed 20 days after inoculation, and the tumors were weighed. The difference between the experimental group and the control group was compared, and the tumor weight inhibition rate and the effect Q value of the combined drug were calculated.
  • Human breast cancer MDA-MB-435 inoculated in BALB/C nude mice (SPF grade), 18-20 g, female;
  • the well-grown MDA-MB-435 tumor pieces were prepared and homogenized with physiological saline to prepare cell suspensions at a concentration of (1-2) ⁇ 10 7 c ell/ml.
  • Each mouse was inoculated with 0.2 ml of right sac, and randomly divided into groups. The mice were administered on the 7th day after inoculation. The mice were sacrificed on the 18th day after inoculation, and the tumors were weighed. The difference between the experimental group and the control group was compared, and the tumor weight inhibition rate and the effect Q value of the combined drug were calculated.
  • the anti-tumor effect of the injection of the invention combined with paclitaxel injection on human breast cancer MDA-MB-435 transplanted into nude mice is obviously stronger than that of the injection of the present invention and paclitaxel injection, and the experiment proves that the injection of the invention is combined with paclitaxel injection.
  • the liquid has a distinct additive effect.
  • 58 patients with advanced ovarian cancer were randomly divided into the present invention group and the control group, wherein 30 patients in the present invention group were treated with the TC regimen (paclitaxel + carboplatin) in combination with the capsule of the present invention, and 28 patients in the control group, only using the TC regimen, two Baseline data were balanced in the group (p>0.05).
  • Paclitaxel 175 mg/m 2 Day 1
  • 6 capsules of the present invention 3 times/d, continued Take it until the condition progresses or an intolerable toxic side effect occurs.
  • Efficacy and disease control rate The short-term efficacy evaluation was performed once every 2 cycles of chemotherapy, and analyzed by RECIST criteria, which were divided into complete remission (CR), partial remission (PR), stable (SD) and progression (PD). CR+PR calculates the effective rate (RR) and calculates the disease control rate (DCR) by CR+PR+SD. All CR and PR patients were confirmed for efficacy after 4 weeks.
  • the efficiency and disease control rate of the present invention group were significantly higher than those of the control group.
  • Toxic side effects 58 patients were evaluated for toxicity and side effects. The most common side effects were gastrointestinal reactions, myelosuppression, neurotoxicity, and muscle and joint pain. The incidence of 3/4 degree myelosuppression in the present invention group and the control group was 42.5% and 54%, respectively, and the incidence of 3/4 degree febrile neutropenia/infection was 12% and 19%, respectively. There were no deaths; nausea, vomiting, neurotoxicity, and muscle and joint pain were more common in the control group; the fatigue of the present invention was significantly lower than that of the control group.
  • the capsule of the invention combined with paclitaxel and carboplatin has high efficiency in treating advanced ovarian cancer, and the toxicity and side effects of chemotherapy are light, which can effectively improve the quality of life of patients.
  • the capsule of the invention Pharmatech tablets (specification: pollen extract P5 70mg, EA10 4mg), sodium chloride injection (specification 250ml: 2.25g, 250ml / bottle), sodium pentobarbital, olive oil, penicillin sodium for injection (specification 800,000 units / support).
  • urogenital sinus sexual mature ICR mice, 20 females, 10 males, weighing 25 ⁇ 30g, male and female 2: l cage, every morning to check the yin, open the vulva with a small scorpion, such as seeing mating
  • the day of the fetus is the first day of pregnancy
  • the female rats were sacrificed for 16 days
  • the 16-day-old fetus was taken out under sterile conditions.
  • the urogenital sinus is placed in a glass dish containing saline for later use.
  • Modeling Sexually mature ICR male mice, 60, weighing 25-30 g, intraperitoneal injection of pentobarbital sodium anesthesia, abdominal incision under sterile conditions, carefully separating the ventral prostate, implanting 3 in the prostate ventral lobe The urogenital sinus tissue of the 16d gestational age of the same fetal rat, 10 of which were only puncture and not implanted as a sham operation group. After intraperitoneal injection of 20,000 units of penicillin for 3 consecutive days.
  • Group administration no abnormalities were found in group 3 days after operation, which were sham operation group, model group, positive control group (siniton 60 mg/kg), high-dose group (9 g/kg) of the present invention. Dose group (3 g/kg) and low dose group (1 g/kg). The rats were administered by continuous intragastric administration for 28 days at a dose of 0.1 ml/l0 g, and the sham-operated group and the model group were intragastrically administered with the same amount of olive oil.
  • Test indicators 1 body weight, 2 ventral prostate wet weight and prostate index (prostate wet weight / mouse weight), 3 ventral prostate tissue pathological changes (see Table 13 for scoring criteria).
  • the capsule of the invention 1 ⁇ 9g/kg administered by intragastric administration for 28 days can significantly reduce the wet weight of the ventral lobe and the prostate index of the ventral lobe in mice with benign prostatic hyperplasia induced by urogenital sinus implantation; significantly improve the urogenital sinus implantation Pathological changes of fibroblast proliferation, glandular enlargement, glandular epithelial hyperplasia and glandular endocrine secretion in the prostatic hyperplasia of benign prostatic hyperplasia mice; significantly reduce uterine genital sinus implantation-induced benign prostatic hyperplasia mouse ventral prostate Glandular area and glandular epithelial height. It can be seen that the capsule of the invention has a significant therapeutic effect on prostatic hyperplasia induced by urogenital sinus implantation in mice.
  • the present invention has a certain inhibitory effect on the growth of human lung cancer A549, liver cancer QGY, LM-3, SMMC-7721, S180 sarcoma, W256 carcinosarcoma, etc. transplanted in nude mice, the injection of the present invention and Capsules combined with low-dose cisplatin, cyclophosphamide, gemcitabine hydrochloride, imiprazole, mitomycin, Lupron, docetaxel, paclitaxel and carboplatin, human lung cancer A549, human liver cancer LM-3, SMMC-7721
  • the growth inhibition of S180 sarcoma, W256 carcinosarcoma, pancreatic cancer, prostate cancer, breast cancer and ovarian cancer has obvious additive effects, and has a combined drug effect.
  • the capsule of the invention has a significant therapeutic effect on prostate hyperplasia in mice.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 60 mesh, extracted by a 600L ⁇ 2 supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • the extraction temperature and separation temperature are respectively 40 ° C and 45 ° C, maintaining the outlet temperature of the first stage analytical reactor and the secondary analytical reactor are 50 ° C and 35 ° C respectively;
  • liquid CO 2 is added by high pressure pump at a flow rate of 2 t / h Pressed into the CO 2 preheater to become a fluid in supercritical state, enter the extraction kettle, maintain the pressure of 20Mpa, extract the coix seed oil;
  • the CO 2 fluid dissolved in the coix seed oil enters the separation column, controls the separation column pressure 7Mpa, and separates Coix seed oil;
  • the CO 2 gas from the separation column enters the primary and secondary analytical reactors, respectively, and maintains the pressures of 7Mpa and 6Mpa respectively, discards the impurities such as water obtained by analysis, and the CO 2 gas becomes liquid CO 2 through the condenser. , recycling, continuous extraction for 2.5h, to obtain coix seed oil;
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 80 mesh, extracted with a 600L ⁇ 2 supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • the extraction temperature and separation temperature are respectively 40 ° C and 40 ° C, maintaining the outlet temperature of the first stage analytical reactor and the secondary analytical reactor are 20 ° C and 15 ° C respectively;
  • liquid CO 2 is pumped at a flow rate of 1 t / h by high pressure pump Pressed into the CO 2 preheater, became the fluid in the supercritical state, entered the extraction kettle, maintained the pressure of 22Mpa, extracted the coix seed oil;
  • the CO 2 fluid dissolved in the coix seed oil entered the separation column, controlled the separation column pressure 8Mpa, and separated Coix seed oil;
  • CO 2 gas from the separation column enters the first-stage and second-stage analytical reactors, respectively, and maintains the pressures of 6Mpa and 5Mpa respectively, discards the impurities such as water obtained by analysis, and the CO 2 gas becomes liquid CO 2 through the condenser. , recycling, continuous extraction for 2h, to obtain coix seed oil;
  • the lower layer of waste acetone was removed; the upper layer of the oil solution was taken, and the activated neutral alumina with an oil weight of 8% was added, stirred for 30 minutes, and then filtered; after the filtrate was heated, the activated kaolin was added with an oil weight of 6%, and stirred.
  • the filtrate was recovered under reduced pressure, and then purified water was added for washing.
  • the lower layer of wastewater was removed; the upper layer of oil was dried under reduced pressure with nitrogen, and then re-gripped at 8%.
  • the activated neutral alumina is stirred, placed in a cold place, and filtered.
  • the filtered oil is concentrated under heating and decompression under nitrogen-filling conditions, and then dried and sterilized by dry heat at 170 ° C for 1.5 h.
  • ⁇ m microporous membrane filtration divided into 500ml glass
  • nitrogen is filled and sealed, that is, the coix seed oil is obtained, the yield is 4.9%;
  • the physical and chemical constant is determined as follows: the relative density is 0.920 at 20 ° C, the refractive index is 1.473 at 20 ° C, the acid value is 0.19, the iodine value is 104, and the saponification value is 186.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 10 mesh, extracted with a 600L ⁇ 2 supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • the extraction temperature and separation temperature were respectively 33 ° C and 39 ° C, maintaining the outlet temperature of the first stage analytical reactor and the secondary analytical reactor were 30 ° C and 20 ° C respectively;
  • the liquid CO 2 was pumped at a flow rate of 3 t / h by high pressure pump Pressed into the CO 2 preheater to become a fluid in supercritical state, enter the extraction kettle, maintain the pressure of 19Mpa, extract the coix seed oil;
  • the CO 2 fluid dissolved in the coix seed oil enters the separation column, controls the separation column pressure 9Mpa, and separates Coix seed oil;
  • CO 2 gas coming out of the separation column enters the primary and secondary analytical reactors, respectively, maintaining the pressures of 5Mpa and 4Mpa, discarding the impurities such as water obtained by analysis, and the CO 2 gas is changed into liquid CO 2 through the condenser. , recycling, continuous extraction for 3h, to obtain coix seed oil;
  • the filtered oil is concentrated under heating and decompression under nitrogen-filling conditions, and then dried and sterilized by dry heat at 160 ° C for 2 h, and after cooling for 0.2 ⁇ m.
  • Microporous membrane filtration divided into 500ml glass In the liquid bottle, nitrogen is filled and sealed, that is, the coix seed oil is obtained, the yield is 4.7%; the physical and chemical constant is determined as follows: the relative density is 0.918 at 20 ° C, the refractive index is 1.474 at 20 ° C, the acid value is 0.15, the iodine value is 100, and the saponification value is 194.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 50 mesh, extracted by a 600L ⁇ 2 supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • the extraction temperature and separation temperature are respectively 35 ° C and 42 ° C, maintaining the outlet temperature of the first stage analytical reactor and the secondary analytical reactor are respectively 40 ° C and 30 ° C;
  • liquid CO 2 is passed through the high pressure pump at a flow rate of 1.5 t / h Pressurized into the CO 2 preheater, become the fluid in the supercritical state, enter the extraction kettle, maintain the pressure 21Mpa, extract the coix seed oil;
  • the CO 2 fluid dissolved in the coix seed oil enters the separation column, and controls the separation column pressure 10Mpa, separation
  • separation The coix seed oil is obtained;
  • the CO 2 gas coming out of the separation column enters the primary and secondary analytical reactors successively, and the pressures are maintained at 7 MPa and 5 MPa, respectively, and the impurities such as water obtained by the analysis are discarded, and the CO 2 gas is turned into a liquid CO through the condenser. 2 , recycling, continuous extraction for 2h, to obtain coix seed oil;
  • Refining Take the coix seed oil extracted by supercritical CO 2 , add 70% petroleum oil with 60% oil weight, add 50% 2% NaOH solution according to the acid value, stir for 10 min, and let stand for 19 h. The lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 21 hours, the lower layer of wastewater was removed. The upper layer was taken for the second time, and after standing for 50 hours, the lower layer of wastewater was removed. The upper layer was re-emulsified by 85% acetone.
  • the filtered oil is concentrated under heating and decompression under nitrogen-filling conditions, and then dried under vacuum at 162 ° C for 2 h. After cooling, 0.2 ⁇ m is passed.
  • Microporous membrane filtration divided into 500ml glass In the liquid bottle, nitrogen is filled and sealed, that is, the coix seed oil is obtained, the yield is 4.0%; the physicochemical constant is determined as follows: the relative density is 0.920 at 20 ° C, the refractive index is 1.071 at 20 ° C, the acid value is 0.16, the iodine value is 105, and the saponification value is 192.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 30 mesh, extracted by a 600L ⁇ 2 supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • the column was separated so that the extraction temperature and the separation temperature were 42 ° C and 45 ° C, respectively, and the outlet temperatures of the first stage analytical reactor and the second stage analytical reactor were 35 ° C and 25 ° C, respectively; the liquid CO 2 was passed through the high pressure pump at a flow rate of 2.5 t / h.
  • the activated neutral alumina is stirred, placed in a cold place, filtered, and the filtered oil is concentrated under heating and depressurization under nitrogen-filled conditions, and then dried under reduced pressure at 165 ° C for 1.5 h. Filtered through a 0.2 ⁇ m microporous membrane and dispensed in 500ml glass Infusion bottle, filled with nitrogen, sealed, that is; lotus seed oil, yield 4.3%; determination of its physical and chemical constant: relative density of 0.916 at 20 ° C, refractive index of 1.473 at 20 ° C, acid value of 0.14, iodine value of 101, saponification The value is 192.
  • the chromatographic peak fraction with a retention time of 15.8 min was collected, and the receiving solution was concentrated under reduced pressure at 30 ° C, transferred to a 10 ml sample vial, and nitrogen-dried at room temperature under nitrogen to obtain 1,3-dioleic acid diglyceride.
  • the chromatographic peak fraction with a retention time of 27 min was collected, and the receiving solution was concentrated under reduced pressure at 30 ° C, transferred to a 10 ml sample vial, and nitrogen-dried at room temperature under nitrogen to obtain 1,2-dilinoleic acid glyceride.
  • mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • Mobile phase B 0 to 27 min: 50% to 60%, 27 to 35 min: 90%, 35 to 45 min: 100%
  • Flow rate 18 mL/min
  • UV detection wavelength 208 nm
  • collected chromatographic peak fraction with retention time of 12.6 to 14.2 min concentrated under reduced pressure with a rotary evaporator under a nitrogen atmosphere, transferred to a 10 mL vial with chloroform, and dried under vacuum After drying in a box at 35 ° C for 6 h, it was filled with nitrogen gas, and the dried sample was stored in a freezer in a refrigerator to obtain tri oleic acid glyceride
  • A tri linoleic acid glyceride
  • B 1-oleic acid-2,3-dilinoleic acid glyceride
  • C 1-palmitic acid-2,3-dilinoleic acid glyceride
  • D 1, 3-Dioleic acid-2-linoleic acid glyceride
  • E 1-palmitic acid-2-linoleic acid-3-oleic acid glyceride
  • F 1,3-dipalmitate-2-linoleic acid glycerin Ester
  • G triolein
  • H 1-palmitic acid-2,3-dioleate.
  • A tri linoleic acid glyceride
  • B 1-oleic acid-2,3-dilinoleic acid glyceride
  • C 1-palmitic acid-2,3-dilinoleic acid glyceride
  • D 1, 3-Dioleic acid-2-linoleic acid glyceride
  • E 1-palmitic acid-2-linoleic acid-3-oleic acid glyceride
  • F 1,3-dipalmitate-2-linoleic acid glycerin Ester
  • G triolein
  • H 1-palmitic acid-2,3-dioleate.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • the mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • the above crude product was prepared into a 20 mg/mL solution using mobile phase B, and the injection volume was 1.5 mL each time;
  • Superstar Benetnach TM C 18 (10 mm ⁇ 250 mm, 5 ⁇ m);
  • Gradient conditions Mobile phase B: 0 to 23 min: 50% to 60%, 32 to 43 min: 60% to 90%, 43 to 60 min: 100%; flow rate: 3 mL /min; UV detection wavelength: 208nm, collect the chromatographic peak fraction with retention time of 31.2 ⁇ 34.7min, concentrate under reduced pressure with nitrogen under the protection of nitrogen, transfer to 10mL vial with chloroform, 35°C in vacuum drying oven After drying for 6 hours, nitrogen was charged, and the dried sample was stored in a freezer in a refrigerator to obtain 1-palmitic acid-2,3-dilinoleic acid glyceride monomer.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • the mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • the above crude product was prepared into a 20 mg/mL solution using mobile phase B, and the injection volume was 1.5 mL each time;
  • Superstar Benetnach TM C 18 (10 mm ⁇ 250 mm, 5 ⁇ m);
  • Gradient conditions Mobile phase B: 0 to 23 min: 50% to 60%, 32 to 43 min: 60% to 90%, 43 to 60 min: 100%; flow rate: 3 mL /min; UV detection wavelength: 208nm, collect the chromatographic peak fraction with retention time of 32.9 ⁇ 35.1min, concentrate under reduced pressure with nitrogen under the protection of nitrogen, transfer to 10mL vial with chloroform, 35°C in vacuum drying oven After drying for 6 hours, nitrogen was charged, and the dried sample was stored in a freezer in a refrigerator to obtain 1-palmitic acid-2,3-dioleate.
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • Another name is the coix seed oil, the weighed oil and water are separately heated to 60 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification, the homogenizer low pressure is 6MPa, the high pressure is 30MPa, the recycling is homogeneous 4 times , the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 8.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. Stir to the specified amount Evenly spare;
  • coix seed oil the oil ester and the water phase are separately heated to 70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification, the homogenizer low pressure is 12 MPa, the high pressure is 45 MPa, and the recycling is uniform. All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 7.1 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • Soybean phospholipid for injection 25g
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil ester and the water phase are separately heated to 65 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 10 MPa
  • the high pressure is 30 MPa
  • the recirculation is homogeneous 5 All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 4.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil ester and the water phase are separately heated to 68 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 7 MPa
  • the high pressure is 35 MPa
  • the recirculation is homogeneous 3 All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following ingredients:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and 10% hydroxyethyl ester solution according to the weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and 10% hydroxyethyl ester solution to the rubber In the tank, after heating to 70 ° C, add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 60 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Capsule Select the appropriate pellets according to the size of the capsules, and then dry at 18 °C and relative humidity ⁇ 35%. After the pellets are dried, the pellets are removed, and the pellets are washed with 95% medicinal ethanol. The amount of water is less than 12%. The unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • 1,3-dioleic acid diglyceride 0.55%
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and benzoic acid at a weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and benzoic acid to the gelatin tank in turn, heat to 90 °C, then Add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 56 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule Select the appropriate pellet mold according to the size of the capsule, and then dry it at 26 ° C and relative humidity ⁇ 35%, then remove the size pellets, and then wash the pellets with 95% medicinal ethanol, then continue to dry to contain The amount of water is less than 12%. The unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and potassium sorbate according to the weight ratio of 1:0.9:0.6:0.005; add glycerin, purified water and potassium sorbate to the gelatin tank in turn, and heat to 80 °C. Then add gelatin and stir constantly, vacuum, until the gelatin is completely dissolved, filter the glue, store at 62 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, and then dry it at 28 ° C and relative humidity ⁇ 35%, then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%.
  • the unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and chlorhexidine acetate according to the weight ratio of 1:1.0:0.5:0.008; add glycerin, purified water and chlorhexidine acetate to the gelatin tank in turn, and heat to 85 After °C, add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 56 °C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, dry it at 30 ° C, relative humidity ⁇ 35%, and then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%.
  • the unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • 1,3-dioleic acid-2-linoleic acid glyceride 15.01%
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • the coix seed oil the oil and the water phase are separately heated to 60 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the homogenizer has a low pressure of 7 MPa, a high pressure of 26 MPa, and a recycling homogenization of 5 times.
  • the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil and the water phase are separately heated to 70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the homogenizer low pressure is 11 MPa
  • the high pressure is 48 MPa
  • the recycling is homogenized 6 times.
  • the particles below 2 ⁇ m should be not less than 95%
  • particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 7.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • Soybean phospholipid for injection 25g
  • coix seed oil contains the following ingredients:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil and the water phase are separately heated to 65 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 8 MPa
  • the high pressure is 40 MPa
  • the recirculation is homogeneous 4 times.
  • the particles below 2 ⁇ m should be not less than 95%
  • particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following ingredients:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and 10% hydroxyethyl ester solution according to the weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and 10% hydroxyethyl ester solution to the rubber In the tank, after heating to 70 ° C, add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 59 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, dry it at 16 °C and relative humidity ⁇ 35%, then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%.
  • the unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • 1,3-dioleic acid-2-linoleic acid glyceride 18.50%
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and benzoic acid at a weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and benzoic acid to the gelatin tank in turn, heat to 90 °C, then Add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 60 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule Select the appropriate pellet mold according to the size of the capsule, and then dry it at 26 ° C and relative humidity ⁇ 35%, then remove the size pellets, and then wash the pellets with 95% medicinal ethanol, then continue to dry to contain The amount of water is less than 12%. The unqualified capsules are removed by visual inspection, printed and packaged.
  • coix seed oil contains the following ingredients:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and potassium sorbate according to the weight ratio of 1:0.9:0.6:0.005; add glycerin, purified water and potassium sorbate to the gelatin tank in turn, and heat to 80 °C. Then add gelatin and stir constantly, vacuum, until the gelatin is completely dissolved, filter the glue, store at 62 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Capsule Select the appropriate pellets according to the size of the capsules, and then dry at 20 °C and relative humidity ⁇ 35%, then remove the pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%. The unqualified capsules are removed by visual inspection, printed and packaged.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)

Abstract

一种从薏苡仁中提取的含有13种甘油酯的薏苡仁油、制剂及其应用。该薏苡仁油中含有下述5种甘油二酯类成分和8种甘油三酯类成分（按质量百分比计）：1,3-二油酸甘油二酯（0.40-0.58%），1-亚油酸-3-油酸甘油二酯（0.91-1.31%），1,2-二油酸甘油二酯（0.24-0.35%），1-油酸-2-亚油酸甘油二酯（0.66-0.95%），1,2-亚油酸甘油酯（0.33-0.47%），三亚油酸甘油酯（4.87-6.99%），1-油酸-2,3-二亚油酸甘油酯（13.00-18.69%），1-棕榈酸-2,3-二亚油酸甘油酯（5.25-7.54%），1,3-二油酸-2-亚油酸甘油酯（13.23-19.02%），1-棕榈酸-2-亚油酸-3-油酸甘油酯（10.26-14.75%），1,3-二棕榈酸-2-亚油酸甘油酯（2.28-3.28%），三油酸甘油酯（14.44-20.76%）和1-棕榈酸-2,3-二油酸甘油酯（8.06-11.58%）。所述薏苡仁油能在抗肿瘤或治疗炎症的药物中应用。

Description

含有13种甘油酯的薏苡仁油、制剂及其应用 技术领域
本发明涉及药学领域，具体而言，本发明涉及一种薏苡仁油、制剂、制备方法及其在制备抗肿瘤药物中的应用。
背景技术
薏苡仁是禾本科薏苡属植物薏苡Coix lacryma-jobi L.var ma-yuen(Roman.)Stapf的成熟干燥种仁，为利水渗湿药，很久以来为药食两用品种。现代研究发现薏苡仁具有镇痛抗炎、免疫调节、抗溃疡、降血脂和减肥等药理作用。近年来，国内外学者通过TLC、HPLC-MS、GC等方法对薏苡仁的化学成分进行了研究，发现其含有多种活性成分，主要包括薏苡仁酯、甘油三酯类、脂肪酸类、内酰胺类、薏苡仁内酯、糖类、甾醇类、三萜类等化合物。其中，酯类是首先被发现的具有抗肿瘤活性的成分，也是报道最多最受关注的化学成分。虽然目前在中国临床上以薏苡仁油为有效成分的康莱特注射剂已得到普遍应用，但其使用的薏苡仁油成分较复杂，除含有甘油三酯成分外，还含有甘油一酯、甘油二酯以及脂肪酸酯等，这必然会使实际生产过程中的质量控制和临床用药安全面临很大的挑战。
本发明以薏苡仁粉为原料，采用超临界二氧化碳萃取、碱化、中性氧化铝和高岭土纯化等步骤，得到了一种薏苡仁油有效部位；通过对其活性成分的分离与鉴定，确定了其组成主要为八种甘油三酯成分和五种甘油二酯成分；并进一步对其进行理化常数的检测，确定了其最优酸值、碘值、皂化值、折光率和相对密度等。采用本发明所述薏苡仁油用药，成分及组成确定，保证了工业生产中各批次间的质量稳定性。
发明内容
本发明的目的在于提供一种从薏苡仁中提取的薏苡仁油，其特征在于：该薏苡仁油中含有如下质量百分含量的5种甘油二酯类成分和8种甘油三酯类成分：1,3-二油酸甘油二酯0.40～0.58％、1-亚油酸-3-油酸甘油二酯0.91～1.31％、1,2-二油酸甘油二酯0.24～0.35％、1-油酸-2-亚油酸甘油二酯0.66～0.95％、1,2-二亚油酸甘油酯0.33～0.47％、三亚油酸甘油酯4.87～6.99％、1-油酸-2,3-二亚油酸甘油酯13.00～18.69％、1-棕榈酸-2,3-二亚油酸甘油酯5.25～7.54％、1,3-二油酸-2-亚油酸甘油酯13.23～19.02％、1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26～14.75％、1,3-二棕榈酸-2-亚油酸甘油酯2.28～3.28％、三油酸甘油酯14.44～20.76％和1-棕榈酸-2,3-二油酸甘油酯8.06～11.58％。
优选的，上述5种甘油二酯成分和8种甘油三酯成分的质量百分含量为：1,3-二油酸甘油二酯0.45～0.55％、1-亚油酸-3-油酸甘油二酯1.03～1.25％、1,2-二油酸甘油二酯0.27～0.33％、1-油酸-2-亚油酸甘油二酯0.75～0.91％、1,2-二亚油酸甘油酯0.37～0.45％、三亚油酸甘油酯5.47-6.69％、1-油酸-2,3-二亚油酸甘油酯14.63～17.88％、1-棕榈酸-2,3-二亚油酸甘油酯5.9～7.21％、1,3-二油酸-2-亚油酸甘油酯14.88～18.19％、1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55～14.11％、1,3-二棕榈酸-2-亚油酸甘油酯2.57～3.14％、三油酸甘油酯16.25～19.86％和1-棕榈酸-2,3-二油酸甘油酯9.07～11.08％；
更优选的，上述5种甘油二酯成分和8种甘油三酯成分的质量百分含量为：1,3-二油酸甘油二酯0.49～0.51％、1-亚油酸-3-油酸甘油二酯1.12～1.16％、1,2-二油酸甘油二酯0.29～0.31％、1-油酸-2-亚油酸甘油二酯0.81～0.85％、1,2-二亚油酸甘油酯0.40～0.42％、三亚油酸甘油酯5.96～6.20％、1-油酸-2,3-二亚油酸甘油酯15.93～16.58％、1-棕榈酸-2,3-二亚油酸甘油酯6.43～6.69％、1,3-二油酸-2-亚油酸甘油酯16.20～16.87％、1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57～13.09％、1,3-二棕榈酸-2-亚油酸甘油酯2.79～2.91％、三油酸甘油酯17.69～18.42％和1-棕榈酸-2,3-二油酸甘油酯9.87～10.27％。
上述含量均指甘油二酯或甘油三酯化合物在薏苡仁油中的质量百分含量，以本发明所 述方法制备得到的薏苡仁油为原料，经过制备色谱分离得到5个甘油二酯单体化合物和8个甘油三酯单体化合物，称重、计算而得。也可根据本领域常规分析方法得出。
其中，所述薏苡仁油按脂肪油检测理化常数为：20℃时相对密度0.916～0.920，20℃时折光率1.471～1.474，酸值＜0.2，碘值100～106，皂化值186～195；
本发明所述的薏苡仁油是通过如下方法获得的：
超临界二氧化碳萃取：取薏苡仁粉碎成10目～80目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33～45℃和30～45℃，保持一级解析釜和二级解析釜出口温度分别为20～50℃和15～35℃；液态CO2以1～3t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19～23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7～10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5～7Mpa和4～6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2～3h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置18～24h后，除去下层皂脚，取上层用纯化水进行水洗，静置18～24h后，除去下层废水；取上层进行第二次水洗，静置40～50h后，除去下层废水；取上层加油重70％～90％丙酮破乳，静置2～4h后，除去下层废丙酮；取上层油溶液，加入油重3％～8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重2％～6％高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1～2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加入油重8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经160～170℃减压干热灭菌1～2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得；
优选地，所述精制步骤如下：
取超临界CO2萃取得到的薏苡仁油，加入油重量60％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水；取上层进行第二次水洗，静置46h后，除去下层废水；取上层加油重70％～90％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入油重5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重4％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加入油重8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经160～170℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得。
本发明所述薏苡仁油为淡黄色的澄明液体，气微、味淡；其在石油醚或三氯甲烷中极易溶解，在丙酮中易溶、在乙醇中微溶，在水中不溶。
按照本发明所述方法制备得到的薏苡仁油，依照中国药典2010年版一部附录方法进行检测，其理化常数均为：20℃时相对密度0.916～0.920，20℃时折光率1.471～1.474，酸值＜0.2，碘值100～106，皂化值186～195。其中，药典所述酸值系指中和脂肪、脂肪油或其他类似物质1克中含有的游离脂肪酸所需氢氧化钾的重量(毫克数)。在油脂类产品的质量研究中，酸值是一个重要评价指标，就本申请所述薏苡仁油而言，其酸值均小于0.2，即通过对制备工艺中超临界萃取参数和碱化等纯化工艺的优化，制备得到的薏苡仁油具有如下优点：一方面作为杂质的游离脂肪酸含量极低，成品质量较好；另一方面富集了大量甘油二酯、甘油三酯类活性成分，纯度较高，并且其中甘油二酯和甘油三酯类成分种类明确、含量稳定。 除此之外，其它理化常数，如皂化值、碘值等，多批次样品测得该值变化范围均较小，进一步说明本发明所述薏苡仁油的质量稳定、临床用药更安全。本发明所述制备方法收率高、成本低、产品稳定，适于工业化生产，安全可控。
本发明的又一目的在于提供一种含有薏苡仁油的药物制剂，具体包括本发明所述薏苡仁油及一种或几种药学上可接受的载体。
其中，所述药学上可接受的载体包括药学领域常规的稀释剂、赋形剂、填充剂、乳化剂、粘合剂、润滑剂、吸收促进剂、表面活性剂、崩解剂、润滑剂或抗氧化剂，必要时还可以加入香味剂、甜味剂、防腐剂或着色剂。
所述药学上可接受的载体可以选自：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、大豆磷脂、维生素C、维生素E、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、羟苯乙酯溶液、苯甲酸、山梨酸钾、醋酸氯己定、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、吐温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙或硬脂酸镁。
所述药物制剂可以是口服固体制剂、口服液体制剂或注射剂。
优选的，
所述口服固体制剂选自胶囊剂、片剂、滴丸、颗粒剂、浓缩丸中的一种；所述口服液体制剂选自水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂，或是一种在使用前可用水或其它适宜的载体复配的干燥产品；所述注射剂选自纳米混悬剂、脂质体、乳剂、冻干粉针剂和水针剂中的一种。
更优选的，
所述注射剂包括如下成分：本发明所述薏苡仁油50～350g，注射用大豆磷脂或可供注射用大豆磷脂10～40g，注射用甘油或可供注射用甘油15～50g，注射用水加至1000ml。
其可通过如下方法制备：
称取处方配制量的注射用大豆磷脂或可供注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油或可供注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至60～70℃后，置高压均质机进行高压乳化，乳化时均质机低压为5～12MPa，高压为25～50MPa，再循环均质3～6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8～8.5，优选6.8～7.0，最优选为6.8；
将制得均匀乳剂氮气加压通过小于等于3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
所述胶囊剂包括如下成分：薏苡仁油200～800g，抗氧化剂和/或乳化剂0.20～0.60g，制成1000粒。
其可通过如下方法制备：
胶液配制：按重量比为1:0.6～1.2:0.3～0.8:0.0001～0.01称取适量明胶、纯化水、甘油和防腐剂；依次将甘油、纯化水、防腐剂(选自10％羟苯乙酯溶液、苯甲酸、山梨酸钾和醋酸氯己定中的一种)加入化胶罐内，加热至70℃～90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56～62℃下存放，备用；
药液配制：将配方量的薏苡仁油、抗氧化剂和/或乳化剂(抗氧化剂为维生素E，乳化剂为吐温80)加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在15～30℃、相对湿度小于35％条件下进 行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
本发明通过药效实验表明，所述薏苡仁油及其制剂对多种人肿瘤细胞株均有不同程度的抑制作用，可作为治疗肿瘤疾病药物。
因此，本发明的目的还在于提供一种上述薏苡仁油、药物制剂单独或与铂类、烷化剂类、二氟核苷类、抗生素类、细胞毒类或激素类化学抗肿瘤药物在制备抗肿瘤或炎症药物中的应用。
其中，所述铂类优选为顺铂、卡铂，烷化剂类优选为环磷酰胺，二氟核苷类优选为盐酸吉西他滨，抗生素类优选为米托蒽醌、丝裂霉素，细胞毒类优选为多西他赛、紫杉醇，激素类优选为醋酸亮丙瑞林；所述肿瘤是指早期、中期或晚期的肺癌、肝癌、胰腺癌、前列腺癌、卵巢癌、乳腺癌、肉瘤样癌或癌肉瘤；所述炎症是指前列腺增生。
以下通过实验数据说明本发明所述组合物及其制剂在抗肿瘤或治疗炎症方面的有益效果。
一、体外MTT法测定薏苡仁油及其制剂对8种人肿瘤细胞株的抑制作用
1、实验材料及配制
(1)细胞株：PANC-1(人胰腺癌细胞)、SKOV3(人卵巢癌细胞)、MCF-7(人乳腺癌细胞)、Bcap-37(人乳腺癌细胞)、SMMC-7721(人肝癌细胞)、HepG-2(人肝癌细胞)、A549(人肺癌细胞)、H460(人肺癌细胞)，上述细胞株由上海医药工业研究药理评价研究中心保存，传代维持。
(2)DMEM完全培养基：添加10％新生牛血清(GIBCO BRL)、双抗。
(3)0.25％胰蛋白酶溶液(Trypsin)：购自Invitrogen公司，-20℃保存。
(4)磷酸缓冲液(PBS)：NaCl 8g，KCl 0.2g，Na2HPO41.15g，KH2PO40.2g，溶于1L双蒸水，121℃高压消毒20min，4℃保存。
(5)MTT(AMRESCO)溶液：用PBS配成5mg/ml溶液。
(6)溶解液：每100ml去离子双蒸水含SDS 10g，异丁醇5ml，浓盐酸0.1ml。
2、实验方法
样品对上述细胞株的抑制作用通过MTT法测得。
具体步骤如下：
(1)细胞培养：①将细胞从液氮中取出，在37℃水浴中迅速解冻，细胞在无菌操作台中移入10ml无菌离心管中加6ml细胞培养基，1000转/分钟离心5分钟。弃去上清液，沉淀中加入5～6ml细胞培养基，滴管吹打使其悬浮后移入细胞培养瓶中，置37℃细胞培养箱内。②次日，自培养箱中取出细胞，弃去细胞瓶中细胞培养基，加入5～6ml细胞培养基，置37℃细胞培养箱内。③隔日，自培养箱中取出细胞，弃去细胞瓶中细胞培养基，加入PBS(pH 7.4)2～3ml晃动清洗，倒掉PBS溶液后再重复一次清洗。在培养瓶中加入3～5滴0.25％胰蛋白酶溶液晃动均匀，加盖置于37℃细胞培养箱内3分钟左右，于显微镜下观察发现细胞自培养瓶壁上脱离，加细胞培养基2ml，滴管吹打使细胞完全脱离瓶壁后，分别移入2个干净培养瓶中，加入细胞培养基5～6ml吹打均匀，置于37℃细胞培养箱内。④隔日，重复③步骤。在整个培养过程中，贴壁细胞不允许生长过密，悬浮细胞始终保持对数生长期。
(2)样品及对照品制备：称取适量薏苡仁油样品溶解于DMSO中，得到浓度为10mg/ml 的溶液。再用PBS作梯度稀释，得到浓度10mg/ml、5000μg/ml、2500μg/ml、1250μg/ml、625μg/ml、312.5μg/ml的稀释样品。
(3)将稀释好的样品加入平底96孔板中，每孔10μl，每点作两个平行测试。将DMSO相应作梯度稀释后加入板中，作为对照。
(4)取处于对数生长期的细胞，细胞经胰酶消化并洗涤后悬浮于含10％小牛血清的培养基中，经苔盼蓝染色排除法计活细胞数，并调节细胞悬浮液密度至2×105个细胞/ml。
(5)将加入细胞的平底96孔板在37℃、5％CO2细胞培养箱中培养48小时。
(6)每孔中加入20μl的5mg/ml MTT溶液，继续在培养箱中保温3～4小时。
(7)每孔加入100μl溶解液，继续在培养箱中保温过夜，使生成的甲臢晶体充分溶解。测定570nm光吸收值。
(8)根据光吸收值计算各样品浓度组的细胞生长抑制率。计算公式如下：
(1－实验孔平均光吸收值/对照孔平均光吸收值)×100％
3、实验结果
表1 不同浓度样品对8种细胞株的生长抑制率(％)
Figure PCTCN2015084294-appb-000001
表2 样品在体外对8种细胞株的IC50(μg/ml)
Figure PCTCN2015084294-appb-000002
4、结论
不同浓度的本发明薏苡仁油在体外对上述8种人肿瘤细胞株有不同程度的抑制作用。
二、测定本发明注射液对移植于裸鼠的人体肿瘤肺癌A549的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)，顺铂(齐鲁制药有限公司)、空白脂肪乳、生理盐水
2、实验方法
取液氮冻存的人体肿瘤肺癌A549细胞株，复苏后，置37℃、5％CO2条件下培养。经传代培养后，取对数生长期的细胞，用生理盐水制备成(1～2)×107cell/ml浓度的细胞悬液，接种于BALB/C裸鼠(SPF级，18～20g，6周龄，雄性)右腋皮下。无菌条件下取体内生长旺盛的人体肿瘤肺癌A549第2代异种移植模型的肿瘤组织，切割成1～2mm3大小的 均匀小块，用套管针于每只裸小鼠右腋皮下接种一块。待接种肿瘤被触及后，随机分组，按实验设计方案给药。所应用的饲料、垫料、笼具及接触的器械等均应高压消毒后使用，裸鼠置于层流架中饲养。并开始动态观察和测试肿瘤大小及动物体重。三周左右处死各组动物，剖取肿瘤称重，按下列公式计算肿瘤抑制率：
肿瘤抑制率％＝[(对照组平均瘤重—给药组平均瘤重)/对照组平均瘤重]×100％合并用药的效应根据金氏公式计算Q值：
Q＝Ea+b/(Ea+Eb-Ea×Eb)
其中，Ea+b为合并用药的抑瘤率，Ea和Eb分别为A药和B药的抑瘤率。如Q值0.85-1.15为相加(+)，大于1.15为增强(++)。
3、实验结果
表3 对人肺癌A549(皮下接种)异种接种于裸小鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000003
与生理盐水阴性对照组比较：*P＜0.05，**P＜0.01。
4、实验结论
本发明注射液剂量25ml/kg、12.5ml/kg、6.25ml/kg，按照iv×10qd方案给药，对移植于裸鼠的人体肺癌A549的生长有明显抑制作用。
本发明注射液合并顺铂对移植于裸鼠的人体肺癌A549的抑瘤作用明显强于本发明注射液和顺铂单独给药，具有明显的相加作用。
三、测定本发明注射液对移植于裸鼠的人体肿瘤肝癌QGY生长的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、阿霉素(Pfizer Italia S.r.l)、空白脂肪乳、生理盐水
2、实验方法
取液氮冻存的人体肿瘤肝癌QGY细胞株，复苏后，置37℃、5％CO2条件下培养。其他同“二、2”。
3、实验结果
表4 对人肝癌QGY(皮下接种)异种接种于裸小鼠模型抗肿瘤疗效试验(肿瘤重量计)
Figure PCTCN2015084294-appb-000004
与生理盐水阴性对照组比较：*P＜0.05，**P＜0.01。
4、实验结论
本发明注射液剂量25ml/kg、12.5ml/kg、6.25ml/kg，按照iv×10qd方案给药，对移植于裸鼠的人体肝癌QGY的生长有明显抑制作用。
本发明注射液合并阿霉素给药对移植于裸鼠的人体肝癌QGY的抑瘤作用明显强于本发明注射液和阿霉素单独给药。
四、测定本发明注射液对移植于裸鼠的人体肿瘤肝癌LM-3的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)，环磷酰胺(江苏恒瑞医药股份有限公司)，空白脂肪乳、生理盐水
2、实验方法
取液氮冻存的人体肿瘤肝癌LM-3细胞株，复苏后，置37℃、5％CO2条件下培养。其他同“二、2”。
3、实验结果
表5 对人肝癌LM-3(皮下接种)异种接种于裸小鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000005
Figure PCTCN2015084294-appb-000006
与生理盐水阴性对照组比较：*P＜0.05，**P＜0.01。
4、实验结论
本发明注射液剂量25ml/kg、12.5ml/kg、6.25ml/kg，按照iv×10qd方案给药，对移植于裸鼠的人体肝癌LM-3的生长有明显抑制作用。
本发明注射液合并环磷酰胺给药对移植于裸鼠的人体肝癌LM-3的抑瘤作用明显强于本发明注射液和环磷酰胺单独给药，具有明显的相加作用。
五、测定本发明注射液对移植于裸鼠的人体肿瘤肝癌SMMC-7721生长的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、盐酸吉西他滨(LILLY FRANCE)、空白脂肪乳、生理盐水
2、实验方法
取液氮冻存的人体肿瘤肝癌SMMC-7721细胞株，复苏后，置37℃、5％CO2条件下培养。其他同“二、2”。
3、实验结果
表6 对人肝癌SMMC-7721(皮下接种)异种接种于裸小鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000007
与生理盐水阴性对照组比较：*P＜0.05，**P＜0.01。
4、实验结论
本发明注射液剂量25ml/kg、12.5ml/kg、6.25ml/kg，按照iv×10qd方案给药，对移植 于裸鼠的人体肝癌SMMC-7721的生长有明显抑制作用。
本发明注射液合并盐酸吉西他滨给药对移植于裸鼠的人体肝癌AMMC-7721的抑瘤作用明显强于本发明注射液和化疗单独给药，具有明显的相加作用。
六、测定本发明注射液对移植于小鼠S180肉瘤的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、环磷酰胺(CTX)、咪托蒽醌(DHAD)、丝裂霉素(MMC)、生理盐水；
S180肉瘤：接种于昆明种小鼠，19-21g，雌性；
2、实验方法
取生长良好的S180腹水，用生理盐水1:4稀释，制备成约(1-2)×107cell/ml的细胞悬液，每只小鼠腋皮下接种0.2ml，随机分组，如表7剂量次日起给药。接种后十日脱颈处死动物，解剖取瘤块，比较各剂量组瘤重之大小，计算抑制率。
3、实验结果
表7 对S180肉瘤接种于小鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000008
与对照组比较：**P＜0.01，*P＜0.05。
4、实验结论
本发明注射液合并CTX、DHAD和MMC抑瘤作用明显强于本发明注射液和化疗单独给药，具有明显的相加作用。
七、测定本发明注射液对移植于大鼠W256癌肉瘤的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、环磷酰胺(CTX)、生理盐水
W256癌肉瘤：接种于Wistar大鼠，50-60g，雌性；
2、实验方法
取生长旺盛的大鼠W256腹水，用生理盐水稀释制备成约(1-2)×107cell/ml的细胞悬液，接种于大鼠右腋部皮下，0.2ml/鼠，于接种后次日随机分组并开始给药，二周后解剖动物，取瘤称重，比较实验组与对照组的差异，计算瘤重抑制率。
3、实验结果
表8 对W256癌肉瘤接种于大鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000009
Figure PCTCN2015084294-appb-000010
与对照组比较：**P＜0.01，*P＜0.05。
4、实验结论
本发明注射液合并CTX抑瘤作用明显强于本发明注射液和化疗单独给药，具有明显的相加作用。
八、测定本发明注射液对移植于裸鼠的PENC-1人胰腺癌的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、盐酸吉西他滨、生理盐水
PENC-1人胰腺癌细胞：接种于BALB/C裸鼠，16-18g，雌性；
2、实验方法
取生长良好PENC-1人胰腺癌瘤块，接种于4周龄雌性BALB/C裸鼠皮下,随机分组并开始给药,停止给药1周后处死小鼠,取瘤称重，比较实验组与对照组的差异，计算瘤重抑制率。
3、实验结果
表9 对PENC-1人胰腺癌接种于裸鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000011
本发明注射液合并盐酸吉西他滨抑瘤作用明显强于本发明注射液和化疗单独给药，具有明显的相加作用。
九、测定本发明注射液对移植于裸鼠的FC-3M人体前列腺癌的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、醋酸亮丙瑞林(Lupron)、生理盐水
FC-3M人体前列腺癌：接种于BALB/C裸鼠，17-21g，雄性；
2、实验方法
取生长良好FC-3M瘤块，用生理盐水以1:4制备成匀浆，每只小鼠腋皮下接种0.2ml,随机分组并于次日给药,接种后21日处死小鼠,取瘤称重，比较实验组与对照组的差异，计算瘤重抑制率。
3、实验结果
表10 对FC-3M人体前列腺癌接种于裸鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000012
Figure PCTCN2015084294-appb-000013
与对照组比较：**P＜0.01，*P＜0.05。
本发明注射液合并Lupron抑瘤作用明显强于本发明注射液和化疗单独给药，具有明显的相加作用。
十、测定本发明注射液对移植于裸鼠的人体乳腺癌Bcap37的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、多西他赛注射液(Taxotere，规格：20mg/瓶)、生理盐水
人体乳腺癌Bcap-37：接种于BALB/C裸鼠(SPF级)，18-20g，雌性；
2、实验方法
取生长良好的Bcap-37瘤块，用生理盐水匀浆制备成(1-2)×107cell/ml浓度的细胞悬液，每只小鼠右腋皮下接种0.2ml，随机分组并于接种后7日给药,接种后20日处死小鼠,取瘤称重，比较实验组与对照组的差异，计算瘤重抑制率及合并用药的效应Q值。
3、实验结果
表11 对人体乳腺癌Bcap-37接种于裸鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000014
与阴性对照组比较：*P＜0.05,**P＜0.01。
本发明注射液合并多西他赛注射液对移植于裸鼠的人体乳腺癌Bcap-37的抑瘤作用明显强于本发明注射液和多西他赛单独给药，实验证明本发明注射液合并多西他赛有明显的相加作用。
十一、测定本发明注射液对移植于裸鼠的人体乳腺癌MDA-MB-435的抑制率
1、实验材料
本发明注射剂(规格：100ml:10g)、紫杉醇注射液注射液(30mg/5ml)、生理盐水
人体乳腺癌MDA-MB-435：接种于BALB/C裸鼠(SPF级)，18-20g，雌性；
2、实验方法
取生长良好的MDA-MB-435瘤块，用生理盐水匀浆制备成(1-2)×107c ell/ml浓度的细 胞悬液，每只小鼠右腋皮下接种0.2ml，随机分组并于接种后7日给药，接种后18日处死小鼠，取瘤称重，比较实验组与对照组的差异，计算瘤重抑制率及合并用药的效应Q值。
3、实验结果
表12 对人体乳腺癌MDA-MB-435接种于裸鼠模型抗肿瘤疗效试验(以肿瘤重量计)
Figure PCTCN2015084294-appb-000015
与阴性对照组比较：*P＜0.05,**P＜0.01。
本发明注射液合并紫杉醇注射液对移植于裸鼠的人体乳腺癌MDA-MB-435的抑瘤作用明显强于本发明注射液和紫杉醇注射液单独给药，实验证明本发明注射液合并紫杉醇注射液有明显的相加作用。
十二、测定本发明胶囊联合化疗治疗卵巢癌的临床效果
1、临床资料与治疗方法
将58例晚期卵巢癌患者随即分为本发明组和对照组，其中本发明组30例，采用TC方案(紫杉醇+卡铂)联合本发明胶囊治疗，对照组28例，仅采用TC方案，两组患者基线资料均衡(p＞0.05)。紫杉醇175mg/m2(第1天)，卡铂AUC＝5(第1天，每3周重复)，根据患者受益情况进行4～6周期化疗，本发明胶囊6粒，3次/d，持续服用，直至病情进展或出现不可耐受的毒副反应。
2、疗效评价
2.1有效率和疾病控制率：每化疗2周期进行近期疗效评价1次，采用RECIST标准进行分析，分为完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)，以CR+PR计算有效率(RR)，以CR+PR+SD计算疾病控制率(DCR)。所有CR及PR患者在4周后进行疗效确认。
2.2毒副反应：采用不良反应通用术语标准(NCI-CTC AE)3.0版进行分析，毒性反应分为0～Ⅴ度。
3、结果
3.1近期疗效：本发明组CR 0例，PR 14例，SD 8例，PD 8例，有效率46.7％，疾病控制率73.3％；对照组CR 0例，PR 11例，SD 6例，PD 11例，有效率39.3％，疾病控制率60.7％。本发明组有效率及疾病控制率均显著高于对照组。
3.2毒副反应：对58例患者均进行毒副反应评价发现最常见的毒副反应有胃肠道反应、骨髓抑制、神经毒性、肌肉关节疼痛等。本发明组和对照组3/4度骨髓抑制的发生率分别为42.5％和54％，3/4度发热性中性粒细胞减少/感染发生率分别为12％和19％，两组患者中均无死亡病例；恶心、呕吐、神经毒性及肌肉关节疼痛的发生在对照组中更为常见；本发明组疲乏的发生明显低于对照组。
由此可见，本发明胶囊联合紫杉醇和卡铂治疗晚期卵巢癌有效率高，化疗相关毒副反应轻,能有效提高患者生活质量。
十三、测定本发明胶囊对尿生殖窦植入法小鼠前列腺增生的影响
1、实验材料
本发明胶囊、
Figure PCTCN2015084294-appb-000016
普适泰片剂(规格：花粉提取物P5 70mg，EA10 4mg)、氯化钠注射液(规格250ml:2.25g，250ml/瓶)、戊巴比妥钠、橄榄油、注射用青霉素钠(规格80万单位/支)。
动物：ICR小鼠，清洁级，禁食过夜后供用。
2、实验方法：
尿生殖窦的准备：取性成熟ICR小鼠，雌性20只，雄性10只，体重25～30g，雌雄2：l合笼，每天早晨检阴栓，用小镊子张开阴门，如见到交配后精液在阴道凝固而成一白色栓子，堵塞于阴道中，说明已交配，以阴栓出现日为妊娠第l天，处死受孕16d的母鼠，无菌条件下取出16d胎龄胎鼠，取出尿生殖窦置于盛有生理盐水的玻璃平皿内备用。
造模：性成熟的ICR雄性小鼠，60只，体重25～30g，腹腔注射戊巴比妥钠麻醉，无菌条件下腹部切口，仔细分离腹叶前列腺，在前列腺腹叶内植入3个16d胎龄同品系胎鼠的尿生殖窦组织，其中10只仅做穿刺不植入组织作为假手术组。术后连续3天每只腹腔注射青霉素2万单位。
分组给药：术后3天未发现异常者分组给药，分别为假手术组、模型组、阳性对照组(舍尼通60mg/kg)、本发明胶囊高剂量组(9g/kg)、中剂量组(3g/kg)和低剂量组(1g/kg)。连续灌胃给药28天，给药量为0.1ml/l0g，假手术组和模型组灌胃给予等量橄榄油。
检测指标：①体重，②腹叶前列腺湿重及前列腺指数(前列腺湿重/小鼠体重)，③腹叶前列腺组织病理变化(评分标准见表13)。
表13 前列腺组织增生病理学检查评分标准
Figure PCTCN2015084294-appb-000017
3、实验结果：
表14 对尿生殖窦植入致前列腺增生小鼠腹叶前列腺的影响(
Figure PCTCN2015084294-appb-000018
n＝10)
Figure PCTCN2015084294-appb-000019
Figure PCTCN2015084294-appb-000020
###P＜0.001vs假手术组；*P＜0.05，**P＜0.01vs模型组，t-test。
表15 对尿生殖窦植入致前列腺增生小鼠腹叶前列腺腺腔及腺腔内分泌物的影响
Figure PCTCN2015084294-appb-000021
n＝10，表中所列为发生该等级病理变化的动物数
表16 对尿生殖窦植入致前列腺增生小鼠腹叶前列腺间质中成纤维细胞增生的影响
Figure PCTCN2015084294-appb-000022
n＝10，表中所列为发生该等级病理变化的动物数
表17 对尿生殖窦植入致前列腺增生小鼠腹叶前列腺上皮形态排列的影响
Figure PCTCN2015084294-appb-000023
n＝10，表中所列为发生该等级病理变化的动物数
表18 对尿生殖窦植入致前列腺增生小鼠腹叶前列腺腺腔面积和腺上皮高度的影响(
Figure PCTCN2015084294-appb-000024
n＝10)
Figure PCTCN2015084294-appb-000025
Figure PCTCN2015084294-appb-000026
##P＜0.01，###P＜0.001vs假手术组；*P＜0.05，**P＜0.01，***P＜0.001vs模型组，t-test。
本发明胶囊1～9g/kg灌胃给药28天可显著降低尿生殖窦植入所致前列腺增生小鼠腹叶前列腺湿重及腹叶前列腺指数升高；明显改善尿生殖窦植入所致前列腺增生小鼠腹叶前列腺间质中成纤维细胞增生、腺腔扩大、腺上皮增生及腺腔内分泌物增加等病理学改变；显著减小尿生殖窦植入所致前列腺增生小鼠腹叶前列腺腺腔面积及腺上皮高度。可见，本发明胶囊对尿生殖窦植入法诱导的小鼠前列腺增生具有显著的治疗作用。
综上所述，本发明薏苡仁油对移植于裸鼠的人体肺癌A549、肝癌QGY、LM-3、SMMC-7721、S180肉瘤、W256癌肉瘤等的生长有一定抑制作用，本发明注射液及胶囊合并小剂量顺铂、环磷酰胺、盐酸吉西他滨、咪托蒽醌、丝裂霉素、Lupron、多西他赛、紫杉醇和卡铂，对人体肺癌A549、人体肝癌LM-3、SMMC-7721、S180肉瘤、W256癌肉瘤、胰腺癌、前列腺癌、乳腺癌和卵巢癌的生长抑制有明显的相加作用，具有合并用药效应。本发明胶囊对小鼠前列腺增生具有显著的治疗作用。
通过试验证实，本发明所述的薏苡仁油及其制剂均能够达到上述试验例所述的效果。
本发明通过以下具体的实施例进一步说明本发明，但不作为本发明的限制。
具体实施方式
实施例1 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成60目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到40℃和45℃，保持一级解析釜和二级解析釜出口温度分别为50℃和35℃；液态CO2以2t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力20Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为7Mpa和6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2.5h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的60℃石油醚，再根据酸值，加入油重45％的2％NaOH溶液，搅拌10min后，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水；取上层进行第二次水洗，静置46h后，除去下层废水；取上层加油重80％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入油重5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重4％经活化的高岭土，搅拌，在45℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加入油重10％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经165℃减压干热灭菌1.5h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得薏苡仁油，收率4.5％；测定其理化常数为：20℃时相对密度0.915，20℃时折光率1.471，酸值0.18，碘值102，皂化值190。
实施例2 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成80目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到40℃和40℃，保持一级解析釜和二级解析釜出口温度分别为20℃和 15℃；液态CO2以1t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力22Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力8Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为6Mpa和5Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的90℃石油醚，再根据酸值，加入油重56％的2％NaOH溶液，搅拌10min后，静置22h后，除去下层皂脚，取上层用纯化水进行水洗，静置20h后，除去下层废水；取上层进行第二次水洗，静置48h后，除去下层废水；取上层加油重90％丙酮破乳，静置2h后，除去下层废丙酮；取上层油溶液，加入油重8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重6％经活化的高岭土，搅拌，在42℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加油重8％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经170℃减压干热灭菌1.5h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得薏苡仁油，收率4.9％；测定其理化常数为：20℃时相对密度0.920，20℃时折光率1.473，酸值0.19，碘值104，皂化值186。
实施例3 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成10目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33℃和39℃，保持一级解析釜和二级解析釜出口温度分别为30℃和20℃；液态CO2以3t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力9Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5Mpa和4Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取3h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的80℃石油醚，再根据酸值，加入油重36％的2％NaOH溶液，搅拌10min后，静置18h后，除去下层皂脚，取上层用纯化水进行水洗，静置18h后，除去下层废水；取上层进行第二次水洗，静置42h后，除去下层废水；取上层加油重75％丙酮破乳，静置2h后，除去下层废丙酮；取上层油溶液，加入油重3％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重2％经活化的高岭土，搅拌，在47℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加油重12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经160℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得薏苡仁油，收率4.7％；测定其理化常数为：20℃时相对密度0.918，20℃时折光率1.474，酸值0.15，碘值100，皂化值194。
实施例4 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成50目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到35℃和42℃，保持一级解析釜和二级解析釜出口温度分别为40℃和30℃；液态CO2以1.5t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力21Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级 解析釜，分别保持压力为7Mpa和5Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的70℃石油醚，再根据酸值，加入油重50％的2％NaOH溶液，搅拌10min后，静置19h后，除去下层皂脚，取上层用纯化水进行水洗，静置21h后，除去下层废水；取上层进行第二次水洗，静置50h后，除去下层废水；取上层加油重85％丙酮破乳，静置4h后，除去下层废丙酮；取上层油溶液，加入油重6％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重5％经活化的高岭土，搅拌，在50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加油重11％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经162℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得薏苡仁油，收率4.0％；测定其理化常数为：20℃时相对密度0.920，20℃时折光率1.471，酸值0.16，碘值105，皂化值192。
实施例5 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成30目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到42℃和45℃，保持一级解析釜和二级解析釜出口温度分别为35℃和25℃；液态CO2以2.5t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力8Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为6Mpa和4Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2.5h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的80℃石油醚，再根据酸值，加入油重40％的2％NaOH溶液，搅拌10min后，静置24h后，除去下层皂脚，取上层用纯化水进行水洗，静置24h后，除去下层废水；取上层进行第二次水洗，静置44h后，除去下层废水；取上层加油重70％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入油重4％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重3％经活化的高岭土，搅拌，在40℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1.5h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加油重9％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经165℃减压干热灭菌1.5h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得；薏苡仁油，收率4.3％；测定其理化常数为：20℃时相对密度0.916，20℃时折光率1.473，酸值0.14，碘值101，皂化值192。
实施例6
薏苡仁油8000mg加入10ml正己烷超声溶解，再用流动相丙酮配制成50mg/mL的薏苡仁油溶液。利用CHEETAH-HP100高效液相制备色谱仪进行分离；流动相：正己烷:丙酮＝94:6(v/v)；每次分离进样量：15ml；色谱柱：Venusil XBP silica(20*250mm,10μm)；流速：18mL/min；ELSD检测器：漂移管温度45℃，载气流速2.0L/min。收集保留时间为15.8min的色谱峰流分，接收液于30℃下减压浓缩后转移到10ml样品瓶中氮气室温下氮气吹干，即得1,3-二油酸甘油二酯。
室温下，无色油状物；
Q-TOF/MS：准分子离子峰[M+Na]+＝m/z 643.5277(Calcd.＝643.5272，C39H72O5Na)，不饱和度＝4，
1H NMR谱和13C NMR谱见表3。
表3 1H NMR和13C NMR谱数据(CDCl3)
Figure PCTCN2015084294-appb-000027
实施例7
薏苡仁油8000mg加入10ml正己烷超声溶解，再用流动相丙酮配制成50mg/mL的薏苡仁油溶液。利用CHEETAH-HP100高效液相制备色谱仪进行分离；流动相：正己烷:丙酮＝94:6(v/v)；每次分离进样量：15ml；色谱柱：Venusil XBP silica(20*250mm，10μm)；流速：18mL/min。ELSD检测器：漂移管温度45℃，载气流速2.0L/min。收集保留时间为17min的色谱峰流分，接收液于30℃下减压浓缩后转移到10ml样品瓶中氮气室温下氮气吹干，即得1-亚油酸-3-油酸甘油二酯。
室温下，无色油状物；
Q-TOF/MS：准分子离子峰[M+Na]+＝m/z 641.5121(Calcd.＝641.5115,C39H70O5Na)，不饱和度＝5；
1H NMR谱和13C NMR谱见表4。
表4 1H NMR和13C NMR谱数据(CDCl3)
Figure PCTCN2015084294-appb-000028
Figure PCTCN2015084294-appb-000029
实施例8
薏苡仁油8000mg加入10ml正己烷超声溶解，再用流动相丙酮配制成50mg/mL的薏苡仁油溶液。利用CHEETAH-HP100高效液相制备色谱仪进行分离；流动相：正己烷:丙酮＝94:6(v/v)；每次分离进样量：15ml；色谱柱：Venusil XBP silica(20*250mm，10μm)；流速：18mL/min。ELSD检测器：漂移管温度45℃，载气流速2.0L/min。收集保留时间为23min的色谱峰流分，接收液于30℃下减压浓缩后转移到10ml样品瓶中氮气室温下氮气吹干，即得1,2-二油酸甘油二酯。
室温下，无色油状物；
Q-TOF/MS：准分子离子峰[M+Na]+＝m/z 643.5277(Calcd.＝643.5272,C39H72O5Na)，不饱和度＝4；
1H NMR谱和13C NMR谱见表5。
表5 1H NMR和13C NMR谱数据(CDCl3)
Figure PCTCN2015084294-appb-000030
Figure PCTCN2015084294-appb-000031
实施例9
薏苡仁油8000mg加入10ml正己烷超声溶解，再用流动相丙酮配制成50mg/mL的薏苡仁油溶液。利用CHEETAH-HP100高效液相制备色谱仪进行分离；流动相：正己烷:丙酮＝94:6(v/v)；每次分离进样量：15ml；色谱柱：Venusil XBP silica(20*250mm，10μm)；流速：18mL/min。ELSD检测器：漂移管温度45℃，载气流速2.0L/min。收集保留时间为24.5min的色谱峰流分，接收液于30℃下减压浓缩后转移到10ml样品瓶中氮气室温下氮气吹干，即得1-油酸-2-亚油酸甘油二酯。
室温下，无色油状物；
Q-TOF/MS：准分子离子峰[M+Na]+＝m/z 641.5121(Calcd.＝641.5115,C39H70O5Na)，不饱和度＝5；
1H NMR谱和13C NMR谱见表6。
表6 1H NMR和13C NMR谱数据(CDCl3)
Figure PCTCN2015084294-appb-000032
Figure PCTCN2015084294-appb-000033
实施例10
薏苡仁油8000mg加入10ml正己烷超声溶解，再用流动相丙酮配制成50mg/mL的薏苡仁油溶液。利用CHEETAH-HP100高效液相制备色谱仪进行分离；流动相：正己烷:丙酮＝94:6(v/v)；每次分离进样量：15ml；色谱柱：Venusil XBP silica(20*250mm，10μm)；流速：18mL/min。ELSD检测器：漂移管温度45℃，载气流速2.0L/min。收集保留时间为27min的色谱峰流分，接收液于30℃下减压浓缩后转移到10ml样品瓶中氮气室温下氮气吹干，即得1,2-二亚油酸甘油酯。
室温下，无色油状物；
Q-TOF/MS：准分子离子峰[M+Na]+＝m/z 639.4964(Calcd.＝639.4959,C39H68O5Na)，不饱和度＝6；
1H NMR谱和13C NMR谱见表7。
表7 1H NMR和13C NMR谱数据(CDCl3)
Figure PCTCN2015084294-appb-000034
Figure PCTCN2015084294-appb-000035
实施例11 三亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为12.6～14.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得三亚油酸甘油酯。
HR-EI-MS：m/z＝878.7344(Calcd.＝878.7363,C57H98O6)，不饱和度＝9。
IR(KBr film)：1746、1170、1098；2928、2856、724；3008、1655cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
表8 实施例11-18所述化合物的1H-NMR图谱数据
Figure PCTCN2015084294-appb-000036
其中，A：三亚油酸甘油酯，B：1-油酸-2,3-二亚油酸甘油酯，C：1-棕榈酸-2,3-二亚油酸甘油酯，D：1,3-二油酸-2-亚油酸甘油酯，E：1-棕榈酸-2-亚油酸-3-油酸甘油酯，F：1,3-二棕榈酸-2-亚油酸甘油酯，G：三油酸甘油酯，H：1-棕榈酸-2,3-二油酸甘油酯。
表9 实施例11-18所述化合物的13C-NMR图谱数据
Figure PCTCN2015084294-appb-000037
其中，A：三亚油酸甘油酯，B：1-油酸-2,3-二亚油酸甘油酯，C：1-棕榈酸-2,3-二亚油酸甘油酯，D：1,3-二油酸-2-亚油酸甘油酯，E：1-棕榈酸-2-亚油酸-3-油酸甘油酯，F：1,3-二棕榈酸-2-亚油酸甘油酯，G：三油酸甘油酯，H：1-棕榈酸-2,3-二油酸甘油酯。
实施例12 1-油酸-2,3-二亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为15.4～17.3min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-油酸-2,3-二亚油酸甘油酯。
HR-EI-MS：m/z＝880.7518(Calcd.＝880.7520,C55H98O6)，不饱和度＝7。
IR(KBr film)：1747，1164，1098；2925，2854，723；3008，1655cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例13 1-棕榈酸-2,3-二亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min，100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为17.4～18.1min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，将上述粗品用流动相B配制成20mg/mL的溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(10mm×250mm,5μm)；梯度条件：流动相B：0～23min：50％～60％，32～43min：60％～90％， 43～60min：100％；流速：3mL/min；紫外检测波长：208nm，收集保留时间为31.2～34.7min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2,3-二亚油酸甘油酯单体。
HR-EI-MS：m/z＝854.7370(Calcd.＝854.7363,C55H98O6)，不饱和度＝7。
IR(KBr Flim)：1746，1165，1095；2926，2854，722；3009，1648cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例14 1,3-二油酸-2-亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为18.4～20.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-油酸-2,3-二亚油酸甘油酯。
HR-EI-MS：m/z＝882.7678(Calcd.＝882.7672,C57H102O6)，不饱和度＝7。
IR(KBr Flim)：1747、1163、1097；2925、2855、723；3007、1655cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例15 1-棕榈酸-2-亚油酸-3-油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离。流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为20.3～21.4min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2-亚油酸-3-油酸甘油酯。
HR-EI-MS：m/z＝856.7519(Calcd.＝856.7513,C55H100O6)，不饱和度＝6。
IR(KBr Flim)：1747、1164、1098；2925、2854、723；3008、1655cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例16 1,3-二棕榈酸-2-亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为25.7～26.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1,3-二棕榈酸-2-亚油酸甘油酯。
HR-EI-MS：m/z＝830.7371(Calcd.＝830.7363,C53H98O6)，不饱和度＝5。
IR(KBr film)：1747、1164、1098；2925、2854、723；3008、1655cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例17 三油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为26.6～27.7min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得三油酸甘油酯。
HR-EI-MS：m/z＝884.7851(Calcd.＝884.7833,C57H104O6)，不饱和度＝6。
IR(KBr film)：1749，1165，1095；2925，2854，723；3004，1654cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例18 1-棕榈酸-2,3-二油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为28.2～29.3min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，将上述粗品用流动相B配制成20mg/mL的溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTMC18(10mm×250mm,5μm)；梯度条件：流动相B：0～23min：50％～60％，32～43min：60％～90％，43～60min：100％；流速：3mL/min；紫外检测波长：208nm，收集保留时间为32.9～35.1min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2,3-二油酸甘油酯。
HR-EI-MS：m/z＝858.7672(Calcd.＝858.7676,C55H102O6)，不饱和度＝5。
IR(KBr film)：1747，1166，1095；2926，2854，722；3003，1654cm-1(弱)。
1H-NMR数据见表8。
13C-NMR数据见表9。
实施例19 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 100g
注射用大豆磷脂 10g
注射用甘油 15g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.50％
1-亚油酸-3-油酸甘油二酯1.31％
1,2-二油酸甘油二酯0.30％
1-油酸-2-亚油酸甘油二酯0.95％
1,2-二亚油酸甘油酯0.41％
三亚油酸甘油酯6.10％
1-油酸-2,3-二亚油酸甘油酯16.18％
1-棕榈酸-2,3-二亚油酸甘油酯6.56％
1,3-二油酸-2-亚油酸甘油酯16.69％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.96％
1,3-二棕榈酸-2-亚油酸甘油酯2.88％
三油酸甘油酯18.30％
1-棕榈酸-2,3-二油酸甘油酯10.18％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油脂与水相分别加热至60℃后，置高压均质机进行高压乳化，乳化时均质机低压为6MPa，高压为30MPa，再循环均质4遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至8.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例20 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 300g
可供注射用大豆磷脂 40g
可供注射用甘油 50g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.40％
1-亚油酸-3-油酸甘油二酯1.05％
1,2-二油酸甘油二酯0.24％
1-油酸-2-亚油酸甘油二酯0.76％
1,2-二亚油酸甘油酯0.33％
三亚油酸甘油酯4.87％
1-油酸-2,3-二亚油酸甘油酯13.00％
1-棕榈酸-2,3-二亚油酸甘油酯5.25％
1,3-二油酸-2-亚油酸甘油酯15.13％
1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26％
1,3-二棕榈酸-2-亚油酸甘油酯3.05％
三油酸甘油酯20.46％
1-棕榈酸-2,3-二油酸甘油酯11.50％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌 均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至70℃后，置高压均质机进行高压乳化，乳化时均质机低压为12MPa，高压为45MPa，再循环均质3遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至7.1；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例21 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 200g
注射用大豆磷脂 25g
可供注射用甘油 30g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.45％
1-亚油酸-3-油酸甘油二酯1.18％
1,2-二油酸甘油二酯0.27％
1-油酸-2-亚油酸甘油二酯0.86％
1,2-二亚油酸甘油酯0.37％
三亚油酸甘油酯5.47％
1-油酸-2,3-二亚油酸甘油酯14.75％
1-棕榈酸-2,3-二亚油酸甘油酯6.01％
1,3-二油酸-2-亚油酸甘油酯18.19％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.11％
1,3-二棕榈酸-2-亚油酸甘油酯2.60％
三油酸甘油酯16.25％
1-棕榈酸-2,3-二油酸甘油酯9.11％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至65℃后，置高压均质机进行高压乳化，乳化时均质机低压为10MPa，高压为30MPa，再循环均质5遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例22 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 150g
可供注射用大豆磷脂 35g
注射用甘油或 30g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.49％
1-亚油酸-3-油酸甘油二酯1.28％
1,2-二油酸甘油二酯0.29％
1-油酸-2-亚油酸甘油二酯0.93％
1,2-二亚油酸甘油酯0.40％
三亚油酸甘油酯5.96％
1-油酸-2,3-二亚油酸甘油酯15.93％
1-棕榈酸-2,3-二亚油酸甘油酯6.43％
1,3-二油酸-2-亚油酸甘油酯16.20％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57％
1,3-二棕榈酸-2-亚油酸甘油酯2.79％
三油酸甘油酯17.69％
1-棕榈酸-2,3-二油酸甘油酯9.87％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至68℃后，置高压均质机进行高压乳化，乳化时均质机低压为7MPa，高压为35MPa，再循环均质3遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例23 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 200g
维生素E 0.20g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.51％
1-亚油酸-3-油酸甘油二酯1.34％
1,2-二油酸甘油二酯0.31％
1-油酸-2-亚油酸甘油二酯0.97％
1,2-二亚油酸甘油酯0.42％
三亚油酸甘油酯6.20％
1-油酸-2,3-二亚油酸甘油酯16.58％
1-棕榈酸-2,3-二亚油酸甘油酯6.69％
1,3-二油酸-2-亚油酸甘油酯16.87％
1-棕榈酸-2-亚油酸-3-油酸甘油酯13.09％
1,3-二棕榈酸-2-亚油酸甘油酯2.91％
三油酸甘油酯18.42％
1-棕榈酸-2,3-二油酸甘油酯10.27％
工艺：
胶液配制：按重量比为1:1.2:0.8:0.01称取适量明胶、纯化水、甘油和10％羟苯乙酯溶液；依次将甘油、纯化水、10％羟苯乙酯溶液加入化胶罐内，加热至70℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在60℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在18℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例24 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 800g
吐温80 0.60g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.55％
1-亚油酸-3-油酸甘油二酯1.44
1,2-二油酸甘油二酯0.33％
1-油酸-2-亚油酸甘油二酯1.05％
1,2-二亚油酸甘油酯0.45％
三亚油酸甘油酯6.69％
1-油酸-2,3-二亚油酸甘油酯17.88％
1-棕榈酸-2,3-二亚油酸甘油酯7.21％
1,3-二油酸-2-亚油酸甘油酯14.92％
1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55％
1,3-二棕榈酸-2-亚油酸甘油酯3.14％
三油酸甘油酯19.86％
1-棕榈酸-2,3-二油酸甘油酯11.08％
工艺：
胶液配制：按重量比为1:1.2:0.8:0.01称取适量明胶、纯化水、甘油和苯甲酸；依次将甘油、纯化水、苯甲酸加入化胶罐内，加热至90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在26℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例25 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 500g
维生素E 0.40g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.58％
1-亚油酸-3-油酸甘油二酯1.14％
1,2-二油酸甘油二酯0.35％
1-油酸-2-亚油酸甘油二酯0.83％
1,2-二亚油酸甘油酯0.47％
三亚油酸甘油酯6.99％
1-油酸-2,3-二亚油酸甘油酯18.69％
1-棕榈酸-2,3-二亚油酸甘油酯7.54％
1,3-二油酸-2-亚油酸甘油酯19.02％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.75％
1,3-二棕榈酸-2-亚油酸甘油酯3.28％
三油酸甘油酯15.96％
1-棕榈酸-2,3-二油酸甘油酯9.70％
工艺：
胶液配制：按重量比为1:0.9:0.6:0.005称取适量明胶、纯化水、甘油和山梨酸钾；依次将甘油、纯化水、山梨酸钾加入化胶罐内，加热至80℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在62℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在28℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例26 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 600g
吐温80 0.3g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.45％
1-亚油酸-3-油酸甘油二酯1.26％
1,2-二油酸甘油二酯0.27％
1-油酸-2-亚油酸甘油二酯0.88％
1,2-二亚油酸甘油酯0.36％
三亚油酸甘油酯6.15％
1-油酸-2,3-二亚油酸甘油酯16.31％
1-棕榈酸-2,3-二亚油酸甘油酯6.66％
1,3-二油酸-2-亚油酸甘油酯16.77％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.89％
1,3-二棕榈酸-2-亚油酸甘油酯2.88％
三油酸甘油酯18.30％
1-棕榈酸-2,3-二油酸甘油酯10.18％
工艺：
胶液配制：按重量比为1:1.0:0.5:0.008称取适量明胶、纯化水、甘油和醋酸氯己定；依次将甘油、纯化水、醋酸氯己定加入化胶罐内，加热至85℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在30℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例27 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 100g
注射用大豆磷脂 10g
注射用甘油 15g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.42％
1-亚油酸-3-油酸甘油二酯1.25％
1,2-二油酸甘油二酯0.25％
1-油酸-2-亚油酸甘油二酯0.81％
1,2-二亚油酸甘油酯0.35％
三亚油酸甘油酯5.13％
1-油酸-2,3-二亚油酸甘油酯14.09％
1-棕榈酸-2,3-二亚油酸甘油酯5.74％
1,3-二油酸-2-亚油酸甘油酯15.01％
1-棕榈酸-2-亚油酸-3-油酸甘油酯10.95％
1,3-二棕榈酸-2-亚油酸甘油酯2.88％
三油酸甘油酯20.75％
1-棕榈酸-2,3-二油酸甘油酯8.69％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至60℃后，置高压均质机进行高压乳化，乳化时均质机低压为7MPa，高压为26MPa，再循环均质5遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例28 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 300g
可供注射用大豆磷脂 40g
可供注射用甘油 50g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.46％
1-亚油酸-3-油酸甘油二酯1.20％
1,2-二油酸甘油二酯0.28％
1-油酸-2-亚油酸甘油二酯0.90％
1,2-二亚油酸甘油酯0.38％
三亚油酸甘油酯5.71％
1-油酸-2,3-二亚油酸甘油酯15.11％
1-棕榈酸-2,3-二亚油酸甘油酯6.02％
1,3-二油酸-2-亚油酸甘油酯15.45％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.20％
1,3-二棕榈酸-2-亚油酸甘油酯3.20％
三油酸甘油酯17.14％
1-棕榈酸-2,3-二油酸甘油酯9.22％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至70℃后，置高压均质机进行高压乳化，乳化时均质机低压为11MPa，高压为48MPa，再循环均质6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至7.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例29 本发明薏苡仁油注射液的制备
处方：
薏苡仁油 200g
注射用大豆磷脂 25g
可供注射用甘油 30g
注射用水加至 1000ml
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.50％
1-亚油酸-3-油酸甘油二酯1.31％
1,2-二油酸甘油二酯0.30％
1-油酸-2-亚油酸甘油二酯0.95％
1,2-二亚油酸甘油酯0.41％
三亚油酸甘油酯6.18％
1-油酸-2,3-二亚油酸甘油酯16.03％
1-棕榈酸-2,3-二亚油酸甘油酯6.51％
1,3-二油酸-2-亚油酸甘油酯16.30％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.83％
1,3-二棕榈酸-2-亚油酸甘油酯2.81％
三油酸甘油酯18.10％
1-棕榈酸-2,3-二油酸甘油酯9.95％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至65℃后，置高压均质机进行高压乳化，乳化时均质机低压为8MPa，高压为40MPa，再循环均质4遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例30 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 200g
维生素E 0.20g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.52％
1-亚油酸-3-油酸甘油二酯1.40％
1,2-二油酸甘油二酯0.32％
1-油酸-2-亚油酸甘油二酯1.01％
1,2-二亚油酸甘油酯0.43％
三亚油酸甘油酯6.51％
1-油酸-2,3-二亚油酸甘油酯17.26％
1-棕榈酸-2,3-二亚油酸甘油酯6.84％
1,3-二油酸-2-亚油酸甘油酯17.65％
1-棕榈酸-2-亚油酸-3-油酸甘油酯13.56％
1,3-二棕榈酸-2-亚油酸甘油酯3.07％
三油酸甘油酯19.33％
1-棕榈酸-2,3-二油酸甘油酯10.80％
工艺：
胶液配制：按重量比为1:1.2:0.8:0.01称取适量明胶、纯化水、甘油和10％羟苯乙酯溶液；依次将甘油、纯化水、10％羟苯乙酯溶液加入化胶罐内，加热至70℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在59℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在16℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例31 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 800g
吐温80 0.60g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.56％
1-亚油酸-3-油酸甘油二酯1.11％
1,2-二油酸甘油二酯0.34％
1-油酸-2-亚油酸甘油二酯0.91％
1,2-二亚油酸甘油酯0.46％
三亚油酸甘油酯6.71％
1-油酸-2,3-二亚油酸甘油酯18.01％
1-棕榈酸-2,3-二亚油酸甘油酯7.25％
1,3-二油酸-2-亚油酸甘油酯18.50％
1-棕榈酸-2-亚油酸-3-油酸甘油酯11.90％
1,3-二棕榈酸-2-亚油酸甘油酯2.63％
三油酸甘油酯19.91％
1-棕榈酸-2,3-二油酸甘油酯11.21％
工艺：
胶液配制：按重量比为1:1.2:0.8:0.01称取适量明胶、纯化水、甘油和苯甲酸；依次将甘油、纯化水、苯甲酸加入化胶罐内，加热至90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在60℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在26℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。
实施例32 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 500g
维生素E 0.40g
制成 1000粒
其中，薏苡仁油含有以下成分：
1,3-二油酸甘油二酯0.57％
1-亚油酸-3-油酸甘油二酯1.21％
1,2-二油酸甘油二酯0.34％
1-油酸-2-亚油酸甘油二酯0.86％
1,2-二亚油酸甘油酯0.46％
三亚油酸甘油酯6.85％
1-油酸-2,3-二亚油酸甘油酯18.24％
1-棕榈酸-2,3-二亚油酸甘油酯7.25％
1,3-二油酸-2-亚油酸甘油酯18.61％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.03％
1,3-二棕榈酸-2-亚油酸甘油酯3.01％
三油酸甘油酯18.60％
1-棕榈酸-2,3-二油酸甘油酯11.21％
工艺：
胶液配制：按重量比为1:0.9:0.6:0.005称取适量明胶、纯化水、甘油和山梨酸钾；依次将甘油、纯化水、山梨酸钾加入化胶罐内，加热至80℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在62℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在20℃、相对湿度＜35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得。

Claims (10)

  1. 一种薏苡仁油，其特征在于：该薏苡仁油中含有如下质量百分含量的5种甘油二酯类成分和8种甘油三酯类成分：1,3-二油酸甘油二酯0.40～0.58％、1-亚油酸-3-油酸甘油二酯0.91～1.31％、1,2-二油酸甘油二酯0.24～0.35％、1-油酸-2-亚油酸甘油二酯0.66～0.95％、1,2-二亚油酸甘油酯0.33～0.47％、三亚油酸甘油酯4.87～6.99％、1-油酸-2,3-二亚油酸甘油酯13.00～18.69％、1-棕榈酸-2,3-二亚油酸甘油酯5.25～7.54％、1,3-二油酸-2-亚油酸甘油酯13.23～19.02％、1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26～14.75％、1,3-二棕榈酸-2-亚油酸甘油酯2.28～3.28％、三油酸甘油酯14.44～20.76％和1-棕榈酸-2,3-二油酸甘油酯8.06～11.58％。
  2. 根据权利要求1所述的薏苡仁油，其特征在于：所述薏苡仁油按脂肪油检测理化常数为：20℃时相对密度0.916～0.920，20℃时折光率1.471～1.474，酸值<0.2，碘值100～106，皂化值186～195；所述甘油二酯成分和甘油三酯成分的质量百分含量为：1,3-二油酸甘油二酯0.45～0.55％、1-亚油酸-3-油酸甘油二酯1.03～1.25％、1,2-二油酸甘油二酯0.27～0.33％、1-油酸-2-亚油酸甘油二酯0.75～0.91％、1,2-二亚油酸甘油酯0.37～0.45％、三亚油酸甘油酯5.47～6.69％、1-油酸-2,3-二亚油酸甘油酯14.63～17.88％、1-棕榈酸-2,3-二亚油酸甘油酯5.9～7.21％、1,3-二油酸-2-亚油酸甘油酯14.88～18.19％、1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55～14.11％、1,3-二棕榈酸-2-亚油酸甘油酯2.57～3.14％、三油酸甘油酯16.25～19.86％和1-棕榈酸-2,3-二油酸甘油酯9.07～11.08％；
    优选地，所述甘油二酯成分和甘油三酯成分的质量百分含量为：1,3-二油酸甘油二酯0.49～0.51％、1-亚油酸-3-油酸甘油二酯1.12～1.16％、1,2-二油酸甘油二酯0.29～0.31％、1-油酸-2-亚油酸甘油二酯0.81～0.85％、1,2-二亚油酸甘油酯0.40～0.42％、三亚油酸甘油酯5.96～6.20％、1-油酸-2,3-二亚油酸甘油酯15.93～16.58％、1-棕榈酸-2,3-二亚油酸甘油酯6.43～6.69％、1,3-二油酸-2-亚油酸甘油酯16.20～16.87％、1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57～13.09％、1,3-二棕榈酸-2-亚油酸甘油酯2.79～2.91％、三油酸甘油酯17.69～18.42％和1-棕榈酸-2,3-二油酸甘油酯9.87～10.27％。
  3. 一种权利要求1所述薏苡仁油的制备方法，具体包括如下步骤：
    超临界二氧化碳萃取：取薏苡仁粉碎成10目～80目，采用600L×2超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33～45℃和30～45℃，保持一级解析釜和二级解析釜出口温度分别为20～50℃和15～35℃；液态CO2以1～3t/h的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19～23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7～10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5～7Mpa和4～6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2～3h，得到薏苡仁油；
    精制：取超临界CO2萃取得到的薏苡仁油，加入油重量60％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置18～24h后，除去下层皂脚，取上层用纯化水进行水洗，静置18～24h后，除去下层废水；取上层进行第二次水洗，静置40～50h后，除去下层废水；取上层加油重70％～90％丙酮破乳，静置2～4h后，除去下层废丙酮；取上层油溶液，加入3～8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重2％～6％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1～2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加入油重8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件 下，加热减压浓缩，再经160～170℃减压干热灭菌1～2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得；
    优选地，所述精制步骤如下：
    取超临界CO2萃取得到的薏苡仁油，加入油重量60％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水；取上层进行第二次水洗，静置46h后，除去下层废水；取上层加油重70％～90％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入油重5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入油重4％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加入油重8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油在充氮条件下，加热减压浓缩，再经160～170℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，充氮，密封，即得。
  4. 一种药物制剂，其特征在于含有治疗有效量的权利要求1～3任一所述的薏苡仁油及一种或几种药学上可接受的载体，其中所述药学上可接受的载体包括药学领域常规的稀释剂、赋形剂、填充剂、乳化剂、粘合剂、润滑剂、吸收促进剂、表面活性剂、崩解剂、润滑剂或抗氧化剂，必要时还可以加入香味剂、甜味剂、防腐剂或着色剂；
    其中，所述药学上可接受的载体可以选自：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、大豆磷脂、维生素C、维生素E、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、羟苯乙酯溶液、苯甲酸、山梨酸钾、醋酸氯己定、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、吐温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙或硬脂酸镁。
  5. 根据权利要求4所述药物制剂，其可以是口服固体制剂、口服液体制剂或注射剂；
    其中，
    所述口服固体制剂选自胶囊剂、片剂、滴丸、颗粒剂、浓缩丸中的任何一种；
    所述口服液体制剂选自水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂，或是一种在使用前可用水或其它适宜的载体复配的干燥产品；
    所述注射剂选自纳米混悬剂、脂质体、乳剂、冻干粉针剂和水针剂中的任何一种。
  6. 根据权利要求5所述药物制剂，其特征在于所述注射剂包含如下成分：
    薏苡仁油 50～350g
    注射用大豆磷脂或可供注射用大豆磷脂 10～40g
    注射用甘油或可供注射用甘油 15～50g
    注射用水加至 1000ml。
  7. 根据权利要求6所述药物制剂的制备方法，其特征在于包括如下步骤：
    称取处方配制量的注射用大豆磷脂或可供注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油或可供注射用甘油，并加注射用水至规定量，搅拌均匀备用；
    另称取薏苡仁油，将称取的油酯与水相分别加热至60～70℃后，置高压均质机进行高压乳 化，乳化时均质机低压为5～12MPa，高压为25～50MPa，再循环均质3～6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8～8.5，优选6.8～7，最优选为6.8；
    将制得均匀乳剂氮气加压通过小于等于3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
  8. 根据权利要求5所述药物制剂，其特征在于所述胶囊剂包含如下成分：
    薏苡仁油 200～800g
    抗氧化剂和/或乳化剂 0.20～0.60g
    制成 1000粒。
  9. 根据权利要求8所述药物制剂的制备方法，其特征在于包括如下步骤：
    胶液配制：按重量比为1:0.6～1.2:0.3～0.8:0.0001～0.01称取适量明胶、纯化水、甘油和防腐剂；依次将甘油、纯化水、防腐剂加入化胶罐内，加热至70℃～90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56℃～62℃下存放，备用；
    药液配制：将配方量的薏苡仁油、抗氧化剂和/或乳化剂加入配料罐内，不断搅拌，直至混合均匀；
    压胶囊：根据胶囊大小选择合适的压丸模具，在15℃～30℃、相对湿度小于35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，印字，包装即得；
    其中，
    所述防腐剂选自10％羟苯乙酯溶液、苯甲酸、山梨酸钾和醋酸氯己定中的一种；
    所述抗氧化剂为维生素E，乳化剂为吐温80。
  10. 根据权利要求1所述薏苡仁油在制备抗肿瘤或治疗炎症药物中的应用，
    其中，
    所述抗肿瘤药物可以是薏苡仁油与铂类、烷化剂类、二氟核苷类、抗生素类、细胞毒类和/或激素类化学药物的组合；优选为薏苡仁油与顺铂、卡铂、环磷酰胺、盐酸吉西他滨、米托蒽醌、丝裂霉素、醋酸亮丙瑞林、多西他赛和/或紫杉醇等化学药物的组合；
    所述肿瘤是指早期、中期或晚期的肺癌、肝癌、胰腺癌、前列腺癌、卵巢癌、乳腺癌、肉瘤样癌或癌肉瘤；所述炎症是指前列腺炎或前列腺增生。
PCT/CN2015/084294 2014-07-18 2015-07-17 含有13种甘油酯的薏苡仁油、制剂及其应用 WO2016008440A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP15822401.4A EP3153164B1 (en) 2014-07-18 2015-07-17 Coix seed oil comprising 13 glycerides, formulation and application thereof
CA2954688A CA2954688C (en) 2014-07-18 2015-07-17 Coix seed oil comprising 13 glycerides, formulation and application thereof
NZ726577A NZ726577A (en) 2014-07-18 2015-07-17 Coix seed oil containing 13 glycerides, and pharmaceutical preparation and use thereof
KR1020177001301A KR101893812B1 (ko) 2014-07-18 2015-07-17 13가지 글리세리드를 포함한 의이인오일, 제제 및 그 응용
EA201790116A EA033751B1 (ru) 2014-07-18 2015-07-17 Композиция масла семян коикса, способ ее получения и применение
AP2017009705A AP2017009705A0 (en) 2014-07-18 2015-07-17 Coix seed oil comprising 13 glycerides, formulation and application thereof
SG11201700120XA SG11201700120XA (en) 2014-07-18 2015-07-17 Coix seed oil comprising 13 glycerides, formulation and application thereof
JP2017503165A JP6473802B2 (ja) 2014-07-18 2015-07-17 １３種のグリセリド含むヨクイニン油、製剤及びその応用
PL15822401T PL3153164T3 (pl) 2014-07-18 2015-07-17 Olej z nasion łzawnicy zawierający 13 glicerydów, jego formułowanie i zastosowanie
AU2015291529A AU2015291529B2 (en) 2014-07-18 2015-07-17 Coix seed oil containing 13 glycerides, and pharmaceutical preparation and use thereof
DK15822401.4T DK3153164T3 (da) 2014-07-18 2015-07-17 Coixfrøolie der omfatter 13 glycerider, formulering og anvendelse deraf

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410342342.1A CN105267776B (zh) 2014-07-18 含有13种甘油酯的薏苡仁油、制剂及其应用
CN201410342342.1 2014-07-18

Publications (1)

Publication Number Publication Date
WO2016008440A1 true WO2016008440A1 (zh) 2016-01-21

Family

ID=55073657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/084294 WO2016008440A1 (zh) 2014-07-18 2015-07-17 含有13种甘油酯的薏苡仁油、制剂及其应用

Country Status (13)

Country Link
US (1) US9585929B2 (zh)
EP (1) EP3153164B1 (zh)
JP (1) JP6473802B2 (zh)
KR (1) KR101893812B1 (zh)
AP (1) AP2017009705A0 (zh)
AU (1) AU2015291529B2 (zh)
CA (1) CA2954688C (zh)
DK (1) DK3153164T3 (zh)
EA (1) EA033751B1 (zh)
NZ (1) NZ726577A (zh)
PL (1) PL3153164T3 (zh)
SG (1) SG11201700120XA (zh)
WO (1) WO2016008440A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015113855A1 (de) 2015-08-20 2017-02-23 Andreas Hettich Gmbh & Co. Kg Rotor einer Zentrifuge
CN106390942A (zh) * 2016-11-07 2017-02-15 郑州圣莱特空心微珠新材料有限公司 一种用于印染废水的污水处理剂及其制备方法
CN108624403A (zh) * 2018-04-28 2018-10-09 武汉工程大学 一种低温非有机溶剂提取能源昆虫油脂的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
CN1485418A (zh) * 2002-09-28 2004-03-31 李大鹏 超临界二氧化碳提取薏苡仁粗油方法
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
CN1029662C (zh) * 1992-09-17 1995-09-06 李大鹏 薏苡仁中性油脂及其提取方法
EP0692362B1 (en) * 1994-07-11 2001-12-12 Sumitomo Chemical Company Limited Method for producing thermoplastic resin molded article and mold assembly therefor
JP2002212586A (ja) * 2001-01-19 2002-07-31 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
JP4167849B2 (ja) 2002-04-15 2008-10-22 大鵬 李 植物の果実から抽出した果実油、その抽出方法、医薬組成物およびその用途
CN1234828C (zh) * 2002-11-21 2006-01-04 上海高科联合生物技术研发有限公司 超临界二氧化碳萃取薏苡仁油的方法
CN100485072C (zh) 2004-03-31 2009-05-06 杰富意钢铁株式会社 高刚度高强度薄板钢及其制备方法
CN1778380A (zh) * 2004-11-23 2006-05-31 乔志亚生技股份有限公司 薏仁油萃取的方法及组成分及其疗效
CN100485418C (zh) 2006-12-21 2009-05-06 哈尔滨工业大学 机器人的三角形阵列红外传感器
CN101036761B (zh) * 2007-04-23 2010-05-19 肖志勇 一种薏苡仁油的制备方法
CN101940738A (zh) * 2010-07-27 2011-01-12 辽宁中医药大学 薏苡仁抗癌中药及其制备方法
CN102177978B (zh) * 2011-04-14 2013-01-30 西南大学 薏苡仁米糠及其运用
TWI541017B (zh) * 2012-12-20 2016-07-11 喬本生醫股份有限公司 薏苡子麩皮之萃取物及其應用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
CN1485418A (zh) * 2002-09-28 2004-03-31 李大鹏 超临界二氧化碳提取薏苡仁粗油方法
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3153164A4 *
XIANG, ZHIMIN ET AL.: "Identification of Triacylglycerols in Coix Oil by High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization-Mass Spectrometry", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 33, no. 18, 30 September 2005 (2005-09-30), pages 1436 - 1438, XP008183620 *

Also Published As

Publication number Publication date
CA2954688C (en) 2019-10-29
CN105267776A (zh) 2016-01-27
EP3153164B1 (en) 2019-05-22
KR101893812B1 (ko) 2018-09-04
PL3153164T3 (pl) 2019-11-29
JP6473802B2 (ja) 2019-02-20
CA2954688A1 (en) 2016-01-21
US9585929B2 (en) 2017-03-07
AP2017009705A0 (en) 2017-01-31
EA033751B1 (ru) 2019-11-21
EP3153164A1 (en) 2017-04-12
AU2015291529B2 (en) 2018-04-19
US20160015769A1 (en) 2016-01-21
AU2015291529A1 (en) 2016-12-08
JP2017524047A (ja) 2017-08-24
SG11201700120XA (en) 2017-02-27
EP3153164A4 (en) 2017-05-03
EA201790116A1 (ru) 2017-07-31
NZ726577A (en) 2018-06-29
KR20170014005A (ko) 2017-02-07
DK3153164T3 (da) 2019-08-26

Similar Documents

Publication Publication Date Title
WO2016008439A1 (zh) 含有8种甘油三酯的薏苡仁油、制剂及其应用
WO2016008442A1 (zh) 含有11种甘油三酯的薏苡仁油、制剂及其应用
WO2016008440A1 (zh) 含有13种甘油酯的薏苡仁油、制剂及其应用
WO2016008443A1 (zh) 含有16种甘油酯的薏苡仁油、制剂及其应用
KR102348782B1 (ko) 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물
US9585858B2 (en) Pharmaceutical composition containing 13 triglycerides, and preparations and use thereof
CN105267776B (zh) 含有13种甘油酯的薏苡仁油、制剂及其应用
WO2016008437A1 (zh) 化合物1-棕榈酸-2-亚油酸-3-油酸甘油酯、制剂、制备方法及其应用
WO2016008438A1 (zh) 含有8种甘油三酯的药物组合物、制剂及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15822401

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015291529

Country of ref document: AU

Date of ref document: 20150717

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015822401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015822401

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2954688

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017503165

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020177001301

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201790116

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2954688

Country of ref document: CA